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Carbon nanodots (CNDs) outshined other traditional carbonaceous nanomaterials 
such as carbon nanotubes, fullerenes, etc., due to their unique properties, such as low 
toxicity, high biocompatibility, excellent photoluminescence, and ease of 
functionalization. Past few years, the research has been focused extensively on synthesis, 
and application of the CNDs in various bio-medical fields, yet the full potential in 
understanding the properties and mechanisms needs to be explored. The current research 
dissertation focusses on fundamentals and the applications of selected carbon nanodots in 
three different aspects: biosensing, drug delivery and free radical regulation. The first part 
of the research concentrates on the synthesis of high quantum yield CNDs and their use 
as fluorescence turn off sensor in the detection of iron ions with improved selectivity and 
sensitivity. Upon addition of iron ions, the fluorescence intensity of the CNDs decreases 
in concentration dependent manner, attributing to the charge transfer between CNDs and 
iron ions, which is further verified using electrochemical analysis. The second part of the 
research is focused on the loading of curcumin onto CNDs to enhance the bioavailability 
of the hydrophobic drug. Curcumin release studies show better release in an acidic 
environment (pH-5.0), conferring the chance of more drug release in tumor 
microenvironment compared to normal tissues. Curcumin loaded CNDs present increased 
cellular cytotoxicity in cancer cells even at low concentrations, proving the efficacy of 
the CNDs as drug delivery vehicles. The third part of the research investigates the 
concentration dependent pro-oxidant and antioxidant properties of photoluminescent 
 
 
curcumin-derived nanoparticles (Curc-dots) synthesized from native curcumin. The 
synthesized Curc-dots retained some of the characteristic functional groups of the native 
curcumin with size less than 10 nm. The cell viability studies showed the antioxidant and 
prooxidant effects of the Curc-dots at low and high concentrations, respectively. The 
Curc-dots are taken up by cells with a bright blue fluorescence in cells and demonstrated 
chemo-protective nature when treated with H2O2, a free radical inducer. Overall, the 
findings from this dissertation research opens a wide platform in understanding the 
underlying mechanisms and unique properties of CNDs in various fields of medicine 
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With old societal issues being tackled, new problems are being brought to the 
surface. During the past decade, nanoscience revolutionizes the society with 
advancements in information technology, medicine, transport, energy, defense, food 
safety, and environmental science industry.1 The nanoparticles provide unique properties 
that differ from the traditional bulk solids.2 Nanoparticles (NPs) are clusters of atoms in 
the size range of 1-100 nm and depending on the size, morphology, physical and 
chemical characteristics, are categorized into metal NPs, ceramic NPs, polymeric NPs 
lipid based NPs, and carbon based NPs.3 Carbon based nanoparticles attracted lots of 
attention due to their high mechanical strength, electrical and thermal conductivity, and 
optical properties and can be classified into 0D, 1D, 2D or 3D depending on the overall 
shape and electron movement.4 
Carbon nanodots (CNDs), a relatively new class of carbon based nanomaterials, 
have been attracting a lot of attention due to their unique properties such as stable 
photoluminescence, good biocompatibility and aqueous solubility, and low toxicity.5-6 
Carbon dots were first obtained during the purification of single-walled carbon nanotubes 
in 2004.7 Physical methods such as arc discharge, laser ablation/passivation, plasma 
treatment and chemical methods like ultrasonic/microwave, thermal or hydrothermal 
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oxidation, electrochemical synthesis can be used to synthesize CNDs.6 CNDs are 
carbonaceous nanomaterials with sizes less than 10 nm and have potential applications in 
biosensing, drug delivery, and bioimaging.8-10 CNDs biosensing application: Transition 
metal ions such as iron, copper, zinc, manganese, cobalt and nickel are an integral part in 
cellular processes such as respiration, gene transcription, proliferation and immune 
function.11 Iron, an essential micronutrient is a part of hemoglobin that transports 
oxygenated blood.12 Iron deficiency leads to sepsis in pregnant women and iron overload 
causes neurological disorders such as Parkinson’s and Alzheimer’s.13 Iron homeostasis is 
crucial for survival of living organisms and therefore the levels need to be monitored. 
Various fluorescent materials such as quantum dots, and organic fluorescent dyes are 
being currently used for detection of iron,14-15 but the irreversible photobleaching, 
toxicity and material instability renders their usage.16-17 Therefore, the research has been 
shifted to CNDs which offer stable photoluminescence, low toxicity, short response time 
and resistance to photobleaching. Few reports demonstrated good sensitivity with 
detection confined only to micromolar range.18-20 Despite the recent research, there is still 
a need for selective and sensitive detection of iron in nanomolar range with better 
understanding of the underlying detection mechanism. High quantum yield CNDs were 
synthesized in a cost-effective manner for the sensitive and selective detection of iron 
using microwave synthesizer. The underlying detection mechanism was investigated 
using an electrochemical technique, cyclic voltammetry. The two synthesized CNDs (E-
CNDs and U-CNDs) were well characterized using AFM, TEM for size and morphology, 
whereas XPS, and FTIR were used for surface functional groups. E-CNDs showed a high 
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quantum yield of 64% incorporating high amounts (~12%) of nitrogen. Upon addition of 
Fe (III) ions, CNDs fluorescence intensity decreased in a concentration dependent 
manner with a fast response time of 1 minute which was evaluated using Stern-Volmer 
equation. The synthesized nanoprobes were successfully internalized inside endothelial 
cells and upon addition of Fe (III) ions, demonstrated quenching. The CNDs were able to 
detect iron in real samples such as tap water and human serum which was validated by 
ICP analysis. The underlying quenching reaction, of CNDs by Fe (III), is due to the 
charge transfer between the CNDs and Fe (III) by formation of CND-(Fe (III))n complex. 
The current work demonstrates high quantum yield CNDs as a fluorescence turn off 
sensor in the detection of Fe (III) with improved selectivity, fast response time, and better 
limit of detection than traditional methods.  
CNDs in drug delivery: Curcumin, a natural polyphenolic spice obtained from 
Curcuma Longa is a dietary supplement with anti-microbial, anti-inflammatory, anti-
cancer and antioxidant/pro-oxidant properties.21-23 Regardless of its potential benefits, 
curcumin usage as a chemotherapeutic entity is limited by its poor bioavailability, low 
aqueous solubility, rapid metabolism and elimination.24-26 Various nanoparticle-based 
drug delivery systems such as liposomes, polymeric nanoparticles, and hydrogels were 
formulated for enhancement of curcumin bioavailability and delivery to target site, but 
their usage is limited by low drug entrapment, instability and initial burst release. 
Presence of large number of surface functional groups on CNDs offer high surface for 
drug loading. Loading of curcumin onto CNDs enhances its bioavailability and overall 
drug tolerance with minimal side effects. In the second part of the research, CNDs were 
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used to load curcumin using physical adsorption. The characterized Curcumin loaded 
CNDs (Curc-CNDs) showed characteristic functional groups of curcumin, clearly 
indicating the successful conjugation of curcumin with CNDs. Curcumin release kinetics 
performed at two different physiological pH 7.4 and 5.0, showed controlled drug release, 
which was investigated using Korsmeyer-Peppas equation. The Curc-CNDs showed more 
release of curcumin at pH-5.0, due to weaker interactions of Curc-CNDs in acidic 
environment favoring the release in the tumor microenvironment and elicits its 
therapeutic effects at the target site. Curc-CNDs showed no significant anti-proliferative 
effects on normal cells, while the cancer cells showed notable decrease in the cell 
viability in a concentration dependent manner, which can be attributed to the more 
release of curcumin as observed from the release profile. Intracellular uptake studies 
showed the localization of Curc-CNDs both in the cytoplasm and nucleus with blue 
fluorescence, which might induce dose dependent DNA damage to nuclear as well as 
mitochondrial genome with increase of ROS levels and lipid peroxidation. The 
biocompatible CNDs based drug delivery system can provide loading of hydrophobic 
drugs and transport them to the target site without altering their chemical stability. 
Curcumin nanoparticles: Reactive oxygen species (ROS) such as superoxide 
anions, peroxides and hydroxyl radicals are by-products of cell mediated signaling 
pathways.27 The ROS levels alter during oxidative stress and the inbuilt antioxidant 
mechanisms cope up with the detrimental effects of ROS in high amounts.28 But the 
pathological conditions, such as cancer, neurological disorders, atherosclerosis and 
hypertension29 elevates the ROS levels beyond the control of cell’s antioxidant 
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mechanisms, thereby causing irreparable damage to cellular structures such as nucleic 
acids, proteins and lipids.30-31 Commercially available antibiotics such as butylated 
hydroxyanisole (BHA), butylated hydroxytoluene (BHT) are toxic and causes liver 
damage and carcinogenesis.32 The need for natural anti-oxidants turns the light on 
curcumin, which has both antioxidant and pro-oxidant properties in cells. But the poor 
bioavailability, rapid metabolism and stability confounds the therapeutic effects.26 
Various delivery systems have been formulated to enhance the bioavailability of 
curcumin33, but the stability still remians a question. Limited light is shed on the 
synthesis of curcumin nanoparticles. In this study, we used microwave synthesizer for the 
one pot synthesis of curcumin nanoparticles (Curc dots) from native curcumin. The use of 
ethylene diamine (EDA) as one of the precursor molecules incorporated nitrogen, making 
the Curc dots fluorescent and provides applications in bioimaging. The as-synthesized 
Curc dots are well dispersed in water and demonstrated size less than 10 nm, retaining 
some of the characteristic functional groups of curcumin. The antioxidant effects of Curc 
dots were evalauted using DPPH assay and confirmed using cyclic voltammetry. The 
antioxidation activity was found to be highest even at a low concentration of Curc dots 
(0.05 mg/mL). Curc dots acts as a proton donor to free radical DPPH*, stabilizing it to a 
neutral DPPH molecule. With increase in Curc dots concentration, the DPPH* availabity 
is decreased at the elcetrode surface, thereby reducing the redox peaks. The low 
concentration (0.01-0.08 mg/mL) of Curc dots have no cytotoxic effects on both normal 
and cancer cells, whereas the high concentrations (0.1-1.6 mg/mL) showed significant 
cytotoxicity on the cells. The concentration dependent antioxidant and pro-oxidant effects 
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of Curc dots were further verified using DCFH-DA assay. At low concentrations, less 
ROS is produced and at high concentrations more ROS is generated. The antioxidant or 
pro-oxidant activity depends on structure modification, curcumin concentration, presence 
of metal ions at free radical generation. The decrease in ROS generation can be attributed 
to the transfer of O-methoxy phenolic rings of Curc dots to free radicals, . The nano 
synthesis of curcumin enhances the anti-proliferative effects even at low concentrations 
compared to native curcumin, thereby offering potential in therapy to regulate ROS levels 
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Carbon nanodots (CNDs) offer potential applications in photocatalysis, 
optoelectronics, bio-imaging, and sensing due to their excellent photoluminescence (PL) 
properties, biocompatibility, aqueous solubility, and easy functionalization. Recent 
emphasis on CNDs in the selective detection of metal ions is due to the growing concern 
for human and environmental safety. In this work, two types of fluorescent carbon 
nanodots (CNDs) are synthesized economically from ethylene diamine (E-CNDs) or urea 
(U-CNDs) in a single step microwave process. The as-prepared CNDs exhibit excellent 
PL at an excitation wavelength of 350 nm with a quantum yield of 64% for E-CNDs and 
8.4% for U-CNDs with reference to quinine sulfate. Both E-CNDs and U-CNDs 
demonstrate high selectivity towards Fe (III) ions among different metal ions, by 
fluorescence quenching in a dose dependent manner. The limit of detection of E-CNDs
12 
 
 and U-CNDs is observed to be 18 nM and 30 nM, respectively, in the linear response 
range of 0-2000 µM with a short response time (seconds). The CNDs detect Fe (III) ions 
in tap water and serum sample with no spiking and the recovery was ~100% with the Fe 
(III) samples. Cellular internalization studies confirm the localization of the CNDs and 
the optical imaging sensing of Fe (III) ions inside living cells. A charge transfer 
fluorescence quenching mechanism, specifically between the CNDs and Fe (III), is 
proposed and examined using cyclic voltammetry. The overall characteristics of the E-
CNDs provides a potential sensing platform in highly sensitive and selective detection of 
Fe (III) ions.  
Introduction 
Metal ions are an integral part in various biological and biochemical processes.1 
Iron is an essential micronutrient for the human body and most biological electron 
transfer processes rely on iron proteins.2 Fe3+ is a major component of hemoglobin that 
facilitates oxygen transport in blood.3 Iron deficiency in pregnant women have increased 
risk of anemia and sepsis associated with high mortality and morbidity rates.4 Moreover, 
iron plays an important role in brain development of newborn babies,5 body temperature 
regulation,6 and muscle function.7 Also, overload of iron may lead to neurological 
diseases such as Parkinson’s and Alzheimer’s.8 Current detection techniques such as 
atomic absorption spectrometry and ion chromatography rely on the use of complicated 
sample preparation and instrumentation.9 Therefore, monitoring of iron levels is 
challenging and detection with high sensitivity and selectivity is of great importance. 
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Use of fluorescent materials in the sensitive detection of biologically important 
metal ions has tremendous potential in the field of biomedicine.1 Quantum dots and 
organic fluorescent dyes, due to their high quantum yield, are used widely as contrast 
agents for detection.11 However, irreversible photobleaching and low optical absorption 
cross-section renders the limitation of the organic dyes in detection. Quantum 
nanoparticles have replaced the usage of organic dyes due to their broad absorption 
spectra12 and quantum confinement effect,11 but their instability13 and the presence of 
toxic heavy metals limits their applications for detection in living cells.14-15 Moreover, 
despite all the recent advancements in the field of biosensing, development of sensitive 
and selective fluorescence detection of Fe (III) ions is still a challenge. With this regard, 
effort has been taken in search of small nanoparticles16-17 with better defined PL,18 higher 
quantum yield,19 and good biocompatibility for the detection of biologically significant 
metal ions.20 Fluorescent carbon nanodots (CNDs), in the nanocarbon family, offer 
superior aqueous solubility,18 robust chemical inertness, promising PL properties21 and 
better biocompatibility than heavy metal quantum dots.22-23 Moreover, polarized carbon 
atoms24 and oxygen containing functional groups such as hydroxyl and carboxyl groups 
in the CNDs contribute to the overall hydrophilicity providing a better platform for easy 
functionalization of various organic, inorganic, and biological entities.25-28 High 
sensitivity, short response time, stable PL, and low toxicity29 of the CNDs provides a 
suitable platform for biosensing.30  
In recent years, several reports have been focused on detection of iron using 
CNDs. These studies have shown that nitrogen-doping can effectively enhance 
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fluorescence quantum yield, resulting in high sensitivity and rapid response.31-37 Various 
CNDs exhibited sensitivity towards iron with limits of detection confined to ppm 
levels,38-39 however increasing the quantum yield could result in even more sensitive 
detection. Few reports demonstrated limit of detection (LOD) in nanomolar range using 
CNDs of a good quantum yield.40-42 Moreover, multiple researchers have synthesized 
biocompatible CNDs that enable cell imaging along with iron sensing.40,43-47 Despite all 
the recent advancements, there is still a need for the economical synthesis of an 
appropriate nanoprobe that offers high quantum yield, and improved sensitivity and 
selectivity. Additionally, the underlying detection mechanism is less studied and needs to 
be explored. 
Hydrothermal method or microwave-assisted CNDs synthesis has been well 
established to doping different elements thus tuning the quantum yield.48-53 Herein we use 
a facile, cost effective, one-step microwave synthesis of highly fluorescent, small, water-
soluble CNDs using two different precursor molecules, ethylene diamine (EDA) for E-
CNDs and urea for U-CNDs as a comparison study. The CNDs are well characterized 
and then used in the Fe (III) detection studies. The as synthesized E-CNDs showed the 
LOD of 18 nM with a quantum yield of 64% by incorporating a high amount of nitrogen 
(11-12%), comparable to previously nitrogen doped CNDs-based sensing probes for iron 
detection.32, 36-37, 54 Upon addition of Fe (III) ions, the fluorescence intensity of the CNDs 
was quenched with a fast response time within 1 minute. The quenching of the CNDs 
upon addition of Fe (III) was evaluated using the Stern-Volmer equation. Iron (III) 
detection in real samples such as tap water and human serum was performed as an 
15 
 
application demonstration. Moreover, optical imaging of human endothelial (EA. Hy926) 
cells with Fe (III) incubation shows potential of using CNDs for iron sensing in living 
cells. The current work demonstrates high quantum yield CNDs as a fluorescence turn off 
sensor in the detection of Fe (III) with improved selectivity, fast response time, and better 
limit of detection than traditional methods. Moreover, to further understand the 
quenching reaction, of CNDs by Fe (III), which is inadequately studied, an 
electrochemical technique, cyclic voltammetry, was used to investigate the charge 
transfer between the CNDs and Fe (III) by changing the concentration of CNDs in the Fe 
(III) solutions. 
Methods and Materials 
Citric acid (ACROS Organics), Urea (Aldrich, 99% ACS reagent), 
Ethylenediamine (EDA, Fisher Scientific), quinine sulfate dihydrate, KCl (ACROS 
Organics), CoCl2, FeCl2 (Alfa Aesar), FeCl3, CrCl3, AgNO3, CuCl2, CaCl2, MgCl2, gold 
electrode, Ag/AgCl reference electrode, platinum electrode (Fisher Scientific), DMEM 
media, EA. hy926 cell line (ATCC), pen/strep solution, fetal bovine serum (Sigma 
Aldrich), CCK-8 assay kit (Sigma Aldrich), human serum. These materials were used in 
the present work without any further purification. 
 Fluorescent CNDs (E-CNDS & U-CNDs) were synthesized through a microwave-
assisted procedure. Briefly, 960 mg of citric acid (ACROS Organics) was mixed with 1 
ml EDA and 1 ml of DI water, and pyrolyzed in microwave synthesizer (CEM Corp 
908005 Microwave Reactor) for 18 min at temperature below 150 ºC and 300 W power 
to synthesize E-CNDs. The brown foamy solution was dissolved in 5 ml of DI water and 
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dialyzed through MWCO 1000 membrane (Scientific Fisher) for 24 hrs. Similarly, U-
CNDs were synthesized by mixing 1 g of urea with 1 g of citric acid and 1 ml of DI water 
and pyrolyzed in 150 W microwave for 12 min at 110ºc. The cooled reactant mixture was 
centrifuged at 3500 rpm for 20 min to remove large and aggregated particles. The two 
CNDs solutions were freeze dried for 24 hours using a freeze drier (Labconco Free Zone 
6 Freeze Dryer). 
The synthesized CNDs were characterized using Transmission Electron 
Microscopy (TEM, Carl Zeiss Libra 120 Plus). The CNDs samples were dropped onto 
carbon coated copper grids for analysis. The size was further characterized using Atomic 
Force Microscopy (AFM, Agilent 5600LS AFM) in tapping mode. AFM samples were 
prepared by dropping CNDs solutions onto a freshly cleaved mica surfaces and vacuum 
dried. Fourier transform infrared (FTIR) spectroscopy (Agilent FTIR) was used to 
investigate surface functional groups. XPS (Thermo Scientific ESCALAB Xi+) and EDX 
(Bruker Nano XFlash Detector 5030) were used to determine elemental composition and 
atomic weight % of the as prepared CNDs. Zeta potential of the CNDs (0.05 mg mL-1) 
was measured using Malvern Zetasizer ZEN3600. The optical properties of the CNDs 
were measured using UV-Visible spectroscopy (Varian Cary 6000i) and fluorescence 
spectroscopy (Horiba FluoroMax-4). Excitation-dependent behavior of the as prepared E-
CNDs (0.01 mg mL-1) and U-CNDs (0.1 mg mL-1) was determined using a fluorescence 
spectrophotometer at different excitation wavelengths ranging from 330-450 nm. 
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The fluorescence quantum yield of the as synthesized CNDs was measured with 
Quinine Sulfate (QS) in 0.1M H2SO4 as a standard (QY: 54%) using the following 
equation:53, 55-56 
 







  (2.1) 
 
where, Φ represent the quantum yield, Grad is the gradient from the plot of integrated 
fluorescence intensity vs absorbance and η, refractive index (aqueous solution 1.33); the 
plots of E-CNDs and U-CNDs as a comparison to the standard QS are shown in Figure 
A.S1, respectively. The subscript QS and C denoted quinine sulfate and CNDs 
respectively.  
The decrease in the fluorescence intensity of the CNDs with addition of Fe (III) 
ions was carried out for different time intervals ranging from 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, 
10, 15 min. A 10 µl aliquot of each types of E-CNDs (0.01 mg mL-1) and U-CNDs (0.1 
mg mL-1) was suspended in 100 µl of Fe (III) (10 µM) and 890 µl of water. The 
fluorescence intensity was calculated for each time interval.  
The stability of the CNDs in aqueous solution was measured for every 10 days up 
to 50 days using fluorescence spectrophotometer. The selectivity of the CNDs towards Fe 
(III) ions was determined. Briefly, 50 µM of different metal ions (Ca2+, Co2+, Fe2+, Ag+, 
Cu2+, K+, Fe3+, Cr3+ and Mg2+) were mixed with 10 µl of E-CNDs (0.01 mg mL-1) and U-
CNDs (0.1 mg mL-1). The selectivity of the CNDs towards Fe (III) in the presence of 
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competitive metal ions was tested. The fluorescence spectra were measured for each type 
of the metal ions used. 
Cyclic voltammetry was performed using a three-electrode electrochemical cell 
with a working gold electrode, 3 M Ag/AgCl reference electrode and platinum counter 
electrode. The electrolyte solution is 10 mM Fe (III) ions with different concentrations of 
CNDs in nitrogen-purged deionized water. The samples were run at different scan rates at 
room temperature. 
Human serum samples were centrifuged to remove protein content and the 
supernatant was treated with CNDs at a concentration of 0.1 mg mL-1 to detect the levels 
of Fe (III). Then the serum samples were spiked with different concentrations of Fe (III) 
and recovery rates were calculated based on the standard curve of the Fe (III). Briefly, 10 
µl of E-CNDs (0.01 mg mL-1), 10 µl of different concentrations of Fe (III) and 80 µl of 
human serum were mixed together and incubated for 5 minutes at room temperature and 
the emission spectra was recorded using an excitation wavelength of 350 nm. Similar set 
of experiments were performed with U-CNDs at a concentration of 0.1 mg mL-1. 
Human endothelial cells (EA. Hy926) were cultured in DMEM supplemented 
with 10% FBS and 1% pen/strep antibiotic solution. The cells were seeded on sterilized 
glass cover slips in 24 well plates and incubated at 37 ºC and 5% CO2 for 24 hours, 
followed by incubation with E-CNDs (0.2 mg mL-1) or U-CNDs (0.5 mg mL-1) for 6 
hours. The cells were washed twice with 1x PBS and treated with 10 µM Fe (III) in 
DMEM media for different time intervals (5 min, 30 min and 1 h). As a control, no Fe 
(III) ions were added. The cells were washed twice with 1x PBS and fixed with 4% 
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paraformaldehyde for 12 min. The cells were washed twice with 1x PBS and stained with 
mitotracker green (stains actin filaments) 30 min. The cover slips were mounted on the 
glass slides using mounting media and imaged under confocal microscope (Zeiss Z1 
Spinning Disk Confocal Microscope) at 20X magnification. 
Results and Discussion 
The AFM images show the even dispersion of E-CNDs (Figure 2.1A) on the mica 
surface with an average height of 7 nm. Similarly, U-CNDs (Figure 2.1C) also show an 
even distribution on the mica surface with an average height of 2.4 nm. Since both CNDs 
are smaller than the radius of curvature for the AFM probe, only the height data can be 
used to determine size. The TEM images demonstrate monodisperse, spherical E-CNDs 
(Figure 2.1B) and U-CNDs (Figure 2.1D) with sizes around 7 nm and 2.4 nm, 
respectively, which are in accordance with the height profiles of the AFM images. The 






Figure 2.1. AFM and TEM of CNDs. Atomic force microscopy (AFM) images of E-
CNDs (A) and U-CNDs (C) with their respective height profiles around 7 nm and 2.4 nm 
respectively, and the TEM images of E-CNDs (B) and U-CNDs (D), respectively. 
 
 
Figure 2.2. XPS Spectra of CNDs. XPS survey spectrum of E-CNDs (A) and U-CNDs 
(C) respectively. High resolution C1s peaks of E-CNDs (B) and U-CNDs (D).  
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The XPS survey spectrum of both the E-CNDs (Figure 2.2A) and U-CNDs 
(Figure 2.2C) show the presence of peaks at 285.0, 400.5, and 532.0 eV attributing to 
C1s, O1s and N1s respectively. E-CNDs present intense N1s peak (Figure 2.2A) in 
comparison to the U-CNDs (Figure 2.2C) depicting higher amounts of N incorporated 
into E-CNDs from EDA.57 The C1s spectrum of U-CNDs (Figure 2.2B) show C-C, O-
C=O and C-O-C surface groups whereas E-CNDs (Figure 2.2D) gives one more 
additional C-O functional group. The O1s and N1s spectra for both E-CNDs (Figure 
A.S2A & A.S2B) and U-CNDs (Figure A.S2C & A.S2D) are observed at 531 and 400 eV 
respectively. EDX analysis provides the weight and atomic ratios of C, H, O and N for 
both E-CNDs (Figure A.S3A) and U-CNDs (Figure A.S3B), and higher nitrogen content 
in E-CNDs (11.3% wt) vs. U-CNDs (8.2% wt) was observed. The reaction behind the 
incorporation of more nitrogen into the E-CNDs could be attributed to the faster reaction 
between the amines of EDA with the carboxylic groups of citric acid, compared to 
formation of U-CNDs. The reaction between amides of urea and carboxylic groups of 
citric acid is slower due to the resonance from the double bonded carbon atom of urea.58 
The zeta potential showed the surface charge of the E-CNDs and U-CNDs to be -
7.32±0.92 mV and -38.5±2.72 mV, respectively. The more negative charge of the U-
CNDs is attributed to the higher ratio of COO- groups and the less negative charge of the 
E-CNDs to the presence of positive charged amine groups, which is in accordance with 
the XPS data. The FTIR (Figure A.S4) spectra of both types of CNDs show broad 
absorption bands at 3000-3500 cm-1 assigned to stretching vibrations of O-H and N-H 
corresponding to the carboxylic acid and amine groups, respectively. The bands at 1538, 
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1432, and 1375 cm-1 of the E-CNDs can be assigned to the bending vibrations of N-H, C-
N, and C-H, respectively.59 U-CNDs shows a peak at 1750 cm-1 which can be ascribed to 
the stretching frequencies of –C=O derived from –COOH. Similarly, C=C bending peak 
at 1549 cm-1 and characteristic O-H bending at 1655 cm-1 are observed.60 The FTIR 
results clearly demonstrates the presence of amino, carboxyl and hydroxyl groups on the 
surface of the two CNDs, which attributes to the overall hydrophilicity of the CNDs.  
The UV-Visible spectrum of E-CNDs (Figure 2.3A) and U-CNDs (Figure 2.3B) 
shows shoulder peaks at 250 nm and 245 nm which are attributed to π- π* transitions of 
C=C (aromatic sp2 domains).61 Strong broad peaks at 350 nm and 337 nm are assigned to 
n-π transitions of C=O bond involving functional groups with electron lone pairs on the 
E-CNDs and U-CNDs respectively.40 The strong emission peaks of the E-CNDs (Figure 
2.3A) and U-CNDs (Figure 2.3B) are centered at ~450 nm with an excitation wavelength 
of 350 nm. Both the CNDs exhibit yellow/brown color under daylight and emitted blue 
light under UV light irradiation (Figure 2.3A & 2.3B inset). The excitation dependence 
emission of E-CNDs and U-CNDs is observed at different wavelengths starting from 
330-450 nm with an increment of 30 nm (Figure A.S5), which may be due to the 
fluorescence origin of the CNDs relevant to the sizes, surface states, and functional 
groups. The strongest emission peak is observed at an excitation wavelength of 350 nm 
for E-CNDs.62 With the U-CNDs, strong emission peaks, but less than that of E-CNDs, 
were observed at broad range of (360-420 nm) excitation wavelengths which correspond 
to the broad absorption spectrum (Figure 2.3B). The highest quantum yields of E-CNDs 
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and U-CNDs are measured to be 64.0±1.2% and 8.4±0.7%, respectively, with reference 
to quinine sulfate.63  
 
 
Figure 2.3. Photoluminescent Properties of CNDs. UV-Vis absorption (blue) and PL 
emission (black) of E-CNDs (0.01 mg mL-1) (A) and U-CNDs (0.1 mg mL-1) (B).  
 
The fluorescence intensity of both the E-CNDs (Figure A.S6A) and U-CNDs 
(Figure A.S6B) quenches rapidly within 30 seconds upon addition of Fe (III) ions (60 
µM). The excitation wavelength was 350 nm for this experiment. At the time frame of 1 
minute, the decrease in the fluorescence intensity stabilized and no significant change in 
the fluorescence intensity was observed even after 15 minutes. This clearly shows that the 
CNDs can be used as a fluorescent probe in the detection of Fe (III) ions rapidly within a 
minute. Note that no significant change is observed in the absorption spectra of E-CNDs 
(Figure A.S7A) and U-CNDs (Figure A.S7B) after the addition of Fe (III) (100 μM) ions. 
Figure 2.4A and 2.4B are clearly evidence that, with increase in the concentration 
of Fe (III) (from top to bottom: 0, 1, 2, 5, 10, 20, 50, 100, 200, 500, 1000, 2000, 5000 
µM), the fluorescence intensity of both the E-CNDs and U-CNDs decreased significantly 
with concentration increase of Fe (III), the fluorescence intensity is negligible. Moreover, 
24 
 
there is a linear correlation between the quenching efficiency ((F0-F)/F) and Fe (III) ion 
concentration in both E-CNDs (Figure 2.4C) and U-CNDs (Figure 2.4D), where F0 and F 
represent the fluorescence intensity of the CNDs in the absence and presence of Fe (III) 
ions, respectively. The limit of detection (LOD) is calculated using the signal noise ratio 
S/N=3 for the CNDs based on the plots with the low concentration below sub µM (Figure 
A.S8). The LOD is determined to be 18 nM and 30 nM for E-CNDs and U-CNDs, 
respectively. Table A.S1 lists several publications using CNDs as PL probes for Fe (III) 
detection for a comparison to this work. This work demonstrates good performance for 
Fe (III) detection in terms of the lowest detection limit, sensitivity and a much larger 
dynamic detection range at the similar level of quantum yield to the best performance in 





Figure 2.4. Fluorescence Quenching of CNDs upon Addition of Fe (III) Ions. PL intensity 
of E-CNDs (0.01 mg mL-1) (A) and U-CNDs (0.1 mg mL-1) (B) upon addition of 
different concentrations of Fe (III) ions. Linear plot of E-CNDs (C) and U-CNDs (D) 
fluorescence quenching, (F0-F)/F, versus Fe (III) concentration at 0.5 – 2000 µM for E-
CNDs and 1.0 – 2000 µM for U-CNDs. Lower concentrations of Fe (III) are ploted in 
Figure A.S8. 
 
The stability of the E-CNDs (Figure 2.5A) & U-CNDs (Figure 2.5B) was 
observed for 50 days with an interval of 10 days at a concentration of 0.05 mg mL-1. 
There is no significant decrease in the fluorescence intensity in both types of CNDs. This 
suggests the stability of the CNDs in the aqueous solution, which can be a better entity 
for use in biological solutions. The selectivity of the CNDs towards different metal ions 
(Ca2+, Co2+, Fe2+, Ag+, Cu2+, K+, Fe3+, Cr3+, and Mg2+) of 50 μM concentration was 
demonstrated using fluorescence spectroscopic measurements. Both E-CNDs (0.05 mg 
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mL-1) (Figure 2.5C) and U-CNDs (0.1 mg mL-1) (Figure 2.5D) show significant decrease 
in the fluorescence intensity upon addition of Fe (III) ions in comparison to the other 
metal ions. The quenching efficiency of E-CNDs (Figure A.S9A) and U-CNDs (Figure 
A.S9B) towards Fe (III) was found to be 87±4% and 70±3%, respectively, much higher 
in comparison to other metal ions. The metal ions have no significant effect on the 
fluorescence quenching of E-CNDs (Figure A.S9C) and U-CNDs (Figure A.S9D) but in 
the presence of Fe (III) ions, the decrease in the intensity is obvious (Figure 2.5E & 
2.5F). Note that the counter anions, such as NO3-, Cl- in this study show insignificant 
interference. The insignificance of fluorescence interference with metal ions suggests the 




Figure 2.5. Stability of CNDs and Interference of Fluorescence in Presence of Different 
Cations. Stability of fluorescence intensity of 0.05 mg mL-1 E-CNDs (A) & 0.1 mg mL-1 
U-CNDs (B) with time (days). Representative fluorescence emission spectra of the E-
CNDs (C) and U-CNDs (D) in presence of different cations at a concentration of 50 µM 
in water, and (E) E-CNDs and (F) U-CNDs with mixed 50 μM Fe (III) ions with different 
cations (50 μM). 
 
To demonstrate detection of Fe (III) in real samples, the iron content in both tap 
water and human serum samples were determined using the CNDs. When the E-CNDs 
(Figure A.S10A) and U-CNDs (Figure A.S10B) were added to the tap water and human 
serum, there is a decrease in the fluorescent intensity which indicated the presence of iron 
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present. With the help of the calibration curve between Fe (III) concentration and the 
CNDs fluorescence intensity, E-CNDs and U-CNDs were able to detect the iron content 
in tap water to be 3.8 µM and 1µM, respectively. The iron content in concentrated human 
serum sample was found to be 27.8 µM and 24.6 µM using E-CNDs and U-CNDs, 
respectively. The ability of the CNDs to detect the iron content in real samples was 
validated with inductively coupled plasma optical emission spectrophotometer (ICP 
OES). Standard solutions of Fe (III) (0.1, 1, 5, 10 ppm) were prepared and calibration 
curve was plotted with Fe (III) concentration vs. emission intensity (Figure A.S11). 
Samples of tap water and serum in 3% HNO3 were analyzed with ICP for iron content 
and was found to be 2.56 µM and 28 µM respectively which is in accordance with the 
fluorescence data of the CNDs (Figure 2.4). 
The high quantum yield and excellent photostability allow the as-synthesized 
CNDs to be used in bioimaging. The confocal images show the localization of both the 
CNDs inside the EA. hy926 cells with bright blue fluorescence (Figure 2.6). The cells 
were counter stained with Mito-tracker green (MT green) to label the actin filaments. In 
the absence of Fe (III) ions, no quenching of fluorescence intensity is observed in the 
cells incubated with either E-CNDs or U-CNDs (Figure 2.6A). Quenching of 
fluorescence is observed in the cells incubated with the CNDs upon the addition of Fe 
(III) ions. At time interval of 5 min, there is not much decrease in the fluorescence 
intensity when compared to the control (Figure 2.6B), but after the incubation of Fe (III) 
ions for 30 min, there is a significant decrease in the fluorescence intensity (Figure 2.6C). 
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The fluorescence is almost completely quenched after incubation of Fe (III) ions for 1 h 
(Figure 2.6D).  
 
 
Figure 2.6. Confocal Images. Fluorescence images of EA. hy926 cells incubated with E-
CNDs (0.1mg mL-1, right) and U-CNDs (0.3mg mL-1, left) in the absence of Fe (III) ions 
(A). Fluorescence images of EA. hy926 cells incubated with E-CNDs and U-CNDs in the 
presence of 10µM of Fe (III) for different time intervals of 5 min (B), 30 min (C) and 1 
hour (D). 
 
The possible quenching mechanism of the CNDs in presence of Fe (III) ions was 
investigated. The quenching process may occur due to the formation of a non-fluorescent 
complex, when a fluorescent molecule and a quencher interact together. The process can 
either be static or dynamic quenching which can be fitted to the Stern-Volmer equation.66 
 




where F0 and F represent the fluorescence intensity of the CNDs in the absence and 
presence of Fe (III) ions, respectively, Ksv is the quenching constant, and Q is the 
concentration of the quencher (Fe (III) ions). 
Both the CNDs show good linear correlation with the Fe (III) ion concentration 
following the Stern-Volmer plot. The quenching constant (Ksv) for the low concentration 
linear range (0.01 to 0.5 µM) was determined to be 5.57×104 M-1 and 3.76×104 M-1 for E-
CNDs (Figure A.S8A) and U-CNDs (Figure A.S8B), respectively, by plotting the 
quenching efficiency ((F0-F)/F) vs. Fe (III) ion concentration. The Ksv values for E-CNDs 
(Figure 2.4C) and U-CNDs (Figure 2.4D) was calculated as 1×104 M-1 and 2.3×103 M-1, 
respectively, for the broader linear concentration range of 0.5-2000 µM. The larger 
constant Ksv value suggests faster kinetics of the association of CNDs with Fe (III) at 
lower concentration of CNDs. Upon addition of Fe (III) ions to the CNDs solution, the 
strong blue fluorescence was quenched which was clear from the decrease in the 
fluorescence intensity spectra of both the CNDs (Figure 2.4A & 2.4B). In the presence of 
Fe (III) ions, the fluorescence intensity of the CNDs was quenched but this phenomenon 
was not observed upon the addition of Fe (II) ions (Figure A.S12). In the presence of Fe 
(III) ions, the nitrogen rich CNDs may donate an electron to the Fe (III) to an orbital in 
the half-filled d-shell, resulting in the formation of a low or non-fluorescent complex. 
Hence, a fluorescence quenching reaction is proposed that addition of CNDs to Fe (III) 
solution will form a complex of CNDs-Fe (III), then followed with electron transfer 
between the optical active sites of CNDs and Fe (III) ions where the Fe (III) is being 
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reduced to Fe (II). As a result, the fluorescence of CNDs in the complex CNDs-Fe 
(III)/(II) is quenched. 
 
 
Figure 2.7. Cyclic Voltammograms. Cyclic voltammograms of Fe (III) incubated with 
different concentrations of E-CNDs (A) and U-CNDs (B) at a scan rate of 20 mV s-1. 
 
To further verify the proposed charge transfer quenching process, 
electrochemistry using cyclic voltammograms (CV) of Fe (III) ions in the presence and 
absence of CNDs was performed with the potential window of -0.2 to 0.9 V vs. Ag/AgCl. 
The CV plots of Fe (III) ions have both oxidation and reduction peaks, but the peaks 
started to disappear upon the addition of the CNDs. Moreover, the redox peaks 
disappeared with the increasing concentration of the CNDs (Figure 2.7). This clearly 
states that, as the concentration of the CNDs increased and more CNDs-Fe (III) complex 
formation, electrons from the CNDs are being transferred to the Fe (III) ions resulting in 
the loss of redox peaks. The CVs for E-CNDs present much more decrease in peak 
current than that of U-CNDs, even though the concentration of E-CNDs is much lower. 
The results strongly support that the fluorescence of E-CNDs quenching reaction is 
kinetically faster than the U-CNDs by Fe (III), a good agreement with the Ksv value 
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obtained by the Stern-Volmer equation. Based on the observation, a quenching reaction 
of E-CNDs with Fe (III) is as follows: 
 
E − CND + n(Fe(III)) → E − CND − (Fe(III))n ↔ E − CND − (Fe(II))n 
(2.3) 
 
The n in Eq. 3 is the stoichiometric coefficient (a number greater than 1) of Fe 
ions combine to a single CND through coordinating or chelating interactions due to large 
number of surface functional groups for chelating.67 When CNDs are added to the Fe (III) 
solution, a complex E-CND-(Fe (III))n forms and participates in the redox reaction at the 
working electrode, resulting in E-CND-(Fe (II))n complex. Note that, since the Fe (III) 
molar concentration is orders higher than the CNDs, not all Fe (III) ions form the CND-
Fe (III) complex. The CV redox peaks represent an ensemble of both the free iron ions 
and the complex (Figure 2.7). Due to the association of E-CNDs with Fe (II) after the 
reaction, the diffusion of E-CND-(Fe(II))n complex to the working electrode is slower 
than the free iron ions in the cyclic voltammetry, consequently a broadened oxidation 
peak of Fe (II) in the CVs is observed. The larger separation of oxidation and reduction 
peaks with more CNDs in the solution suggests slower electrochemical kinetics of redox 
reaction of CND-(Fe (III))n/CND-n(Fe (II))n at the electrode surface because of more 
CNDs-(Fe (II/III))n complex formation and less free Fe (III) ions in the solution.
68 In a 
control experiment, the cyclic voltammetry of Fe (II) treated with E-CNDs or U-CNDs 
presents insignificant changes of the redox reaction at electrode surfaces (Figure A.S13 
and A.S14), suggesting that the chelating of CNDs to Fe (II) is weak and electron transfer 
from Fe (II) to CNDs is not in favor. This result indicates the fluorescence quenching 
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would be specifically electron transfer from the CNDs to Fe (III) ions when the complex 
forms, namely oxidation of CNDs and reduction of Fe (III) promoted by applied external 
voltage. Moreover, this control experiment also implies that it is unlikely the adhesion of 
CNDs or a contamination to the electrode surface to cause the slower electrochemical 
kinetics. 
The selectivity of the CNDs can be attributed to the energy level match between 
the photo-excited excitons (PL centers) in CNDs and the level of valence d state orbit of 
the Fe (III) when the CND- (Fe(III))n complex forms, resulting the reduction of Fe(III).
67, 
69 In this work, the Fe (III) valence d state level as an electron acceptor matches the 
CNDs’ PL centers, similar to ref67 for Fe (III) detection, while other metal ions don’t, 
though CNDs might be able to form a complex with other metal ions via chelating 
interactions. This can be further elucidated by the difference of standard reduction 
potential of metal ions. For instance, the standard reduction potential of Fe (III) to Fe (II) 
and Cu (II) to Cu (I) are 0.77 V (NHE) and 0.16 V (NHE), respectively. The Fe (III) is a 
much stronger oxidizing agent (electron acceptor) than Cu (II). Hence, one should not 
expect strong fluorescence quenching with addition of Cu (II) in this case, though the 
CNDs-Cu (II) complex may form due to the presence of amine groups of CNDs. This 
was confirmed by the CVs of Cu2+ in water with and without addition of E-CNDs (Figure 
A.S15) or U-CNDs (Figure A.S16), which don’t show significant changes in shape of the 
CVs while the redox peak currents decrease with addition of CNDs due to formation of 
CND- (Cu(II)n, which indicates decrease of free Cu
2+. Similarly, this principle is 
applicable to other metal ions that the energy level for charge transfer doesn’t match the 
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excitons (PL centers) in CNDs for charge transfer. As a result, no significant interference 
was observed from Ca2+, Co2+, Fe2+, Ag+, Cu2+, K+, Fe3+, Cr3+ and Mg2+ etc. 
Conclusion 
In summary, E-CNDs and U-CNDs synthesized using one step microwave 
synthesis are able to detect Fe (III) ions with high selectivity and sensitivity. The 
synthesized CNDs show good aqueous solubility, excellent stability, and high PL with E-
CNDs quantum yield as high as 64%. A decrease in fluorescence intensity is observed 
with the increase of Fe (III) ions in the CNDs solution. E-CNDs probe provide higher 
sensitive analysis of Fe (III) ions in comparison to U-CNDs probe with limit of detection 
of about 18 nM for E-CNDs and 30 nM for U-CNDs, owing to increase nitrogen content 
in E-CNDs. The CNDs are used as probes to detect Fe (III) in real samples such as tap 
water and human serum without pretreatment, and the results are validated by ICP 
element analysis. Both the CNDs are successfully internalized inside endothelial cells 
with bright blue fluorescence and the phenomenon of fluorescence quenching is observed 
when the cells are incubated with Fe (III), suggesting potential sensing of Fe (III) in 
living cells. The fluorescence quenching of CNDs attributes to the charge transfer 
specifically between CNDs to Fe (III) which is further verified in cyclic voltammetry 
studies. The energy match of the excitons (PL centers) of the CNDs for electron transfer 
to the metal ions is critical for allowed charge transfer quenching mechanism when the 
CNDs-metal ion complex forms. In conclusion, these CNDs can be valuable nanoprobes 
in the sensitive and selective detection of Fe (III) ions in a broad dynamic range 
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DESIGN OF CURCUMIN LOADED CARBON NANODOTS DELIVERY 
SYSTEM: ENHANCED BIOAVAILABILITY, RELEASE KINETICS AND 
ANTICANCER ACTIVITY 
 
This chapter has been submitted for publication as: Arvapalli, Durga; Sheardy, 
Alex; Allado, Kokougan; Chevva, Harish; Wei, Jianjun, Design of Curcumin 
loaded Carbon Nanodots Delivery System: Enhanced Bioavailability, Release 




Despite the potential health benefits of curcumin (Curc) such as antioxidant, 
anticancer and anti-inflammatory, antimicrobial properties, its usage is limited by poor 
bioavailability and low aqueous solubility. Nano–formulations of curcumin has gained lot 
of attention due to their increased bioavailability, solubility, circulation times, targeted 
specificity, decreased biodegradation, better stability, and improved cellular uptake. The 
current study aimed to enhance the bioavailability of curcumin by using carbon nanodots 
(CNDs) as loading vehicles to deliver curcumin due to their excellent biocompatibility, 
aqueous solubility and photoluminescence properties. Two types of CNDs (E-CNDs and 
U-CNDs) were used for curcumin loading and characterized for particle size, 
morphology, encapsulation efficiency, stability, photoluminescence properties, in-vitro 
drug release studies, cellular uptake and anticancer activity. The prepared Curc-loading 
CNDs displayed size around or below 10 nm with good stability. The Curc-E-CNDs  
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demonstrated an encapsulation efficiency of 91%, while the Curc-U-CNDs have an 
encapsulation efficiency of 82%. Curcumin release followed a controlled sustained 
pattern, where a total of 59% and 68% of curcumin was released at 72 hours from Curc-
E-CNDs and Curc-U-CNDs, respectively. Both the Curc-CNDs were uptaken by cells 
and exhibited prominent cytotoxicity towards cancer cells. The results clearly depict the 
role of CNDs as an efficient carrier for curcumin delivery with prolonged release, and 
enhanced bioavailability thereby improving the overall antitumor activity. 
Introduction 
Curcumin, a natural polyphenolic spice obtained from tropical southeast Asian 
plant Curcuma Longa (turmeric) has its applications dated back centuries as a dietary 
supplement1-2 with its anti-inflammatory, analgesic, antiseptic and antioxidant 
properties.1, 3  Phase I clinical trials in humans showed no side effects upon 
administration of curcumin (8 g/day). Curcumin can inhibit cell cycle progression, induce 
apoptosis and halt cell proliferation process in cancer cell lines thereby establishing its 
potential role as an anti-tumor agent.  However, the poor bioavailability, low aqueous 
solubility, poor absorption, rapid degradation, fast metabolism, and systemic elimination 
hinders this elixir drug usage as a chemotherapeutic agent. Moreover, the intracellular 
uptake of curcumin is limited by its hydrophobicity, where curcumin binds to the lipids 
of the cell membrane without entering the cytoplasm.  
Structural and chemical modifications have been implemented to increase the 
bioavailability of curcumin, but are limited due to the low potency of the derivates 
compared to the native curcumin, therefore requiring higher doses to elicit therapeutic 
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responses.16-17 Nano-based drug delivery systems have emerged as an eminent solution to 
overcome the limitations and increase the bioavailability and targetability of curcumin, 
thereby improving the overall anticancer activity.18  Nanoparticles size, shape, and 
surface chemistry plays an important role in the selection of drug delivery vehicles for 
cancer therapy.19 Various nano-formulation based drug delivery systems such as 
liposomes,20-24 polymeric nanoparticles,25-27 and hydrogels28-29 showed promising 
curcumin delivery, however also exhibit some drawbacks. Specifically, use of liposomes 
is limited by low drug entrapment and instability,30 polymeric nanoparticles offer toxicity 
of unreacted monomers and initial burst release of curcumin respectively.31 
Encapsulation of curcumin into nanoparticles improve the solubility and stability of the 
hydrophobic drug overcoming rapid drug metabolism and transports the drug to the target 
site and reduces adverse side effects.32  
Carbon nanodots (CNDs) are spherical low molecular weight luminescent 
particles (<10 nm) with excellent photostability against photobleaching, and possess 
tunable emission spectra, photo-electric activities,33-34 good biocompatibility,35 and low 
toxicity.36-37 These desirable properties of the CNDs opened up several applications in 
photocatalysis,38 bio-sensing,39 bioimaging,40-42 and anti- or pro-oxidation.43-46 While 
tremendous progresses have been made on designing drug carrying nano-vehicles for 
cancer therapy,47-52 limited light is shed on the CNDs.53-56  Due to their superior chemical 
and physical properties, CNDs with large number of surface functional groups offer high 
surface area for drug loading, thereby increasing the solubility of hydrophobic drug 
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which can be used as drug loading vehicles to reach cancer site with better targeting and 
delivery efficiency, thereby reducing the side effects and improving drug tolerance.  
The work is to synthesize curcumin-loaded CNDs with enhance bioavailability, 
loading efficiency and anti-cancer properties along with incorporating the unique 
properties, such as photoluminescence, small size (~10 nm), and stability. In the present 
study, two types of CNDs (E-CNDs and U-CNDs) are functionalized with curcumin for 
examining the bioavailability and eliciting the therapeutic effects. The Curc-CNDs are 
characterized regarding the structure, composite and optical properties. Curcumin release 
kinetics from the complex was investigated using Korsmeyer and Peppas equation. The 
kinetics studies provide information about the pH dependent release of curcumin as a 
function of time. Intracellular and anticancer activities of Curc-CNDs were tested in two 
cancer cell lines, HepG2 and A549 cells, and one normal cell lines, EA. hy926. Curcumin 
loading onto the CNDs increases the bioavailability of in cells compared to native 
curcumin, thereby meeting low concentrations required to elicit anti-cancer effects.  
Methods and Materials 
Citric acid (ACROS Organics), Ethylenediamine, Urea (Fisher Scientific), 
Curcumin (Chem Cruz), phosphate buffer solution (PBS) (Life Tech), quinine sulfate 
dihydrate, methanol (Fisher Scientific), A549 cell line, HepG2 cell line, EA. hy926 cell 
line, DMEM (Dulbecco’s minimum essential medium), EMEM (Eagle’s minimum 
essential medium), and F12 K (Ham's F-12K (Kaighn's) Medium), (ATCC), pen/strep 




E-CNDs and U-CNDs were synthesized as mentioned in our previous work.37 
Briefly, E-CNDs were prepared by dissolving 960 mg of citric acid in 1 mL each of DI 
water and ethylene diamine (EDA) were added. The mixture was pyrolyzed by 300 W 
microwave (CEM Corp 908005 Microwave Reactor) for 18 min at temperature below 
150 ºC. The resulting brown foamy solution was dissolved in 5 mL of DI water for 
purification. U-CNDs were prepared by pyrolyzing urea (1 gram) and citric acid (1 gram) 
in 1 mL of DI water at 110 ºC for 12 min at 150 W power. Large aggregated particles 
were removed by centrifugation. Both samples were purified by dialysis against DI water 
(1000 MWCO) and solid powders were obtained by lyophilization. 
The synthesized E-CNDs and U-CNDs were loaded with curcumin. Briefly, 
curcumin was dissolved in methanol (1:1 w/v) and the solution was added dropwise to 
either E-CNDs or U-CNDs at a concentration of 2 mg/mL. The reactant mixture was 
ultra-sonicated in a water bath for 20 min and shaken on rotary shaker (500 rpm) 
overnight at room temperature. The methanol was evaporated by using rotary evaporation 
and the Curc-CNDs were centrifuged. The pellet was dissolved in known amount of 
methanol and quantified using UV-Vis spectrophotometer (Varian Cary 6000i) at 425 
nm. Curcumin standard curve was plotted with known concentrations. The curcumin 
encapsulation and loading efficiency % was calculated using the formula as follows 
 
Encapsulation efficiency =




Loading efficiency % =
Weight of curcumin CNDs
weight of CNDs
∗ 100 (3.2) 
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Atomic Force Microscopy (Agilent 5600LS AFM), Transmission Electron 
Microscopy (TEM, Carl Zeiss Libra 120 Plus), and zeta potentiometer (Malvern 
Zetasizer ZEN3600) were used for the determination of the size and charge of the CNDs 
before and after functionalization with Curcumin respectively. The samples were 
analyzed by FT-IR spectroscopy (Agilent FTIR) to identify the functional groups of 
curcumin in the functionalized Curc-CNDS. Chemical structure and elemental 
composition of the Curc-CNDs were characterized using XPS (Thermo Scientific 
ESCALAB Xi+) and Raman spectroscopy (Horiba XploRA One Raman Confocal 
Microscope System) respectively. Ultraviolet-visible spectrophotometer (Varian Cary 
6000i) and fluorescence spectrophotometer (Varian Cary Eclipse) were used to 
investigate the optical properties of the Curc-CNDs, respectively. The fluorescence 
quantum yield (QY) of the CNDs before and after Curcumin functionalization was 
determined using Quinine Sulfate (QS) as a standard fluorescent compound in 0.1 M 
H2SO4 using the following equation:
57-58  
 







2  (3.3) 
 
where, Φ represent the quantum yield, Grad is the gradient from the plot of integrated 
fluorescence intensity vs absorbance and η, refractive index (aqueous solution 1.33). The 
subscript QS and C denoted quinine sulfate and CNDs before and after functionalization 




The Curc-CNDs were dissolved in 10mM PBS and incubated at 37 ºC at a pH of 
5 and 7. Samples were taken at different time intervals (0, 0.5, 1, 2, 4, 8, 16, 24, 48, and 
72 h) and centrifuged for 3 min at 1200 rpm to pelletize released curcumin. 
Concentrations of released curcumin was calculated from the curcumin standard curve. 
Curcumin release studies were also carried out in cell culture media to determine the 




Total curcumin in CNDs
∗ 100 (3.4) 
 
The release pattern of the curcumin was analyzed using the formulation derived 
by Korsmeyer and Peppas to analyze the release pattern of drugs, which is given by 
 






) = Log(k) + nLog(t) (3.6) 
 
Where, Mt and M∞ are the fraction of drug released at time t and infinite time, 
respectively, k is a kinetic constant, and n is the release exponent, indicative of transport 
mechanism of drug.59  
HepG2 cells (human hepatocellular cancer cells) were maintained in EMEM 
supplemented with 10% FBS and 1% pen/strep antibiotic solution, A549 cells 
(adenocarcinomic human alveolar basal epithelial cells) were maintained in F12K media 
supplemented with 10% FBS and 1% pen/strep antibiotic solution and EA. hy926 cells 
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were maintained in DMEM media supplemented with 10% FBS and 1% pen/strep 
antibiotic solution. All the cells were kept in an incubator with 5% CO2 at 37 ºC. 
The biocompatibility of E-CNDs, U-CNDs and Curc-CNDs were determined 
using CCK-8 assay. The assay is based on the conversion of WST-8 [2-(2-methoxy-4-
nitrophenyl)-3-(4-nitrophenyl)-5-(2,4disulfophenyl)-2H-tetrazolium, monosodium salt] 
dye to a water-soluble orange colored formazan complex due to the cellular 
dehydrogenase activity. The cell viability is measured at an optical density of 450 nm.60 
The EA. hy926 cells were pre-seeded in 96-well plate overnight and starved in low serum 
media for 24 hours. The respective medium with different concentrations of the CNDs 
and Curc-CNDs (0, 0.1, 0.2, 0.4, 0.8, 1.6, and 3.2 mg/mL) were added to investigate their 
biocompatibility towards both the cancerous cells and normal cells incubated for 24 
hours. Viability of the cells was examined by measuring absorption at 450 nm after 1 hr. 





∗ 100 (3.7) 
 
10,000 cells of HepG2 and A549 were pre-seeded in 96-well plate overnight and 
starved in low serum media for 24 hours. Different concentrations (0, 0.1, 0.2, 0.4, 0.8, 
1.6, and 3.2 mg/mL) of the CNDs and Curc-CNDs were added to HepG2 and A549 cells 
and incubated for 24 hours. Viability was determined using alamar blue assay and % of 




Live/Dead assay were conducted on HepG2 and A549 cells. Cells (1 ×105) were 
seeded on coverslips that were placed in 12 well plates overnight. The medium was 
replaced with different concentrations (0, 0.4, 0.8, and, 1.6 mg/ml) of Curc-E-CNDs and 
Curc-U-CNDs and incubated for 12 hours. The growth medium was replaced with live 
dead reagent (calcein AM and ethidium homodimer-1) dissolved in sterile phosphate 
buffer saline (PBS), and incubated for 45 minutes. The cells were washed thrice with 
PBS and the coverslip was placed on the slide. The cells were imaged under confocal 
microscope (Zeiss Z1 Spinning Disk Confocal Microscope) for intracellular localization 
of thCurc-E-CNDs. The images were collected at 20X magnification. The live cells 
uptake calcein AM and stain green, whereas the dead cells uptake ethidium homodimer-1 
and stain red.  
All data were expressed as mean ± standard error. Each experiment was repeated 
in triplicates and significance was analyzed by multifactor analysis of variance 
(ANOVA) with accepted statistical significance at a level of p < 0.05. 
Results and Discussion 
The successful conjugation of CNDs with curcumin was validated using different 
characterization techniques. The AFM images of Curc-E-CNDs (Figure 3.1A) and Curc-
U-CNDs (Figure 3.1B) showed an even dispersion with average height of 9 nm and 4 nm, 
respectively. Since the radius of curvature of the AFM probe is bigger compared to both 
the Curc-CNDs, only the height data can be used to determine the size. The average 
diameter of the curcumin functionalized Curc-E-CNDs (Figure 3.1C) and Curc-U-CNDs 
(Figure 3.1D) is around 10 nm and 5 nm, respectively, from the TEM images, which is in 
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accordance with the AFM data. The zeta potential of E-CNDs is -7.32±0.9 mV, and upon 
functionalization with curcumin changed to -11.7±1.3 mV at a physiological pH of 7.4. 
Upon functionalization of U-CNDs with curcumin, the zeta potential has changed from -
38.5±2.7 mV to -32.9±3.8 mV. The zeta potential trends observed in both the Curc-CNDs 
suggest the successful adsorption of curcumin onto the CNDs. The higher negative zeta 
potential indicates better stability in aqueous solution.61 This property allows for the 
longer circulation time of the Curc-U-CNDs in the tumor microenvironment, due to 
reduced interaction between serum proteins and the Curc-CNDs.62  
 
 
Figure 3.1. AFM and TEM of Curc-CNDs. Atomic force microscopy (AFM) images of 
Curc-E-CNDs (A) and Curc-U-CNDs (C) with their respective height profiles around 9 
nm and 4 nm respectively, and the TEM images of Curc-E-CNDs (B) and Curc-U-CNDs 
(D), respectively. 
 
The FTIR analysis further confirmed the functionalization of the CNDs with 
curcumin. Native curcumin exhibits characteristic peaks at 3509 cm-1, 3024 cm-1, 1624 
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cm-1, 1275 cm-1 which corresponds to OH stretching of phenol, CH stretching, C=O, C=C 
stretching mode, C-O enol stretching, respectively.63 Both E-CNDs and U-CNDs, after 
functionalization with curcumin exhibit similar characteristic peaks to that of curcumin 
confirming the successful conjugation of CNDs and curcumin (Figure 3.2). Moreover, the 
O-H and N-H stretching of the E-CNDs and U-CNDs is conserved in the Curc-CNDs 
after functionalization (Figure B.S1).39 Raman spectra of both the CNDs shows the 
increase in D band intensity after functionalization with curcumin which can be attributed 
to the carbon atoms excited from sp2 to sp3 hybridization due to the introduction of 
oxygenated functional groups (Figure B.S2).64 
 
 
Figure 3.2. FTIR Spectra of Curc-CNDs. FTIR spectra of Curc-E-CNDs (A) and Curc-U-
CNDs (B) with their characteristic curcumin and CNDs spectra.  
 
XPS spectrum of curcumin depicts the presence of two elements carbon at 285.0 
eV and oxygen at 532.0 eV, respectively (Figure S3A). The XPS spectra of both E-CNDs 
(Figure 3.3A) and U-CNDs (Figure 3.3C) after functionalization with curcumin show the 
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presence of carbon, nitrogen, and oxygen at 285.0, 400.5, and 532.0 eV. The curve fitting 
C1s spectra of Curc-E-CNDs (Figure 3.3B) and Curc-U-CNDs (Figure 3.3D) have 
chemical states at corresponding to C-C, C-O-C, O-C=O and O=C-OH, similar to that of 
the curcumin C1s spectra (Figure B.S3). Similarly, the C1s characteristic peaks of E-
CNDs and U-CNDs are conserved after functionalization with curcumin (Figure B.S4).56 
The additional peak O=C-OH is observed in both the types of CNDs after 
functionalization with curcumin (Figure 3.3B & 3.3D). The O1s spectra of Curc-E-CNDs 
depicts O-H and C=O peaks (Figure B.S5A) and Curc-U-CNDs have presented peaks 
corresponding to O-H and O-C=O (Figure B.S5C), whereas the individual high resolution 
N1s spectra of both the Curc-E-CNDs (Figure B.S5B) and Curc-U-CNDs (Figure B.S5D) 







Figure 3.3. XPS Spectra of Curc-CNDs. XPS survey spectra of Curc-E-CNDs (A) and 
Curc-U-CNDs (C). High resolution C1s (B, D) XPS spectra of Curc-E-CNDs and Curc-
U-CNDs respectively. 
 
In UV-Vis (Figure 3.4A), E-CNDs and U-CNDs have shoulder peaks located at 
250 nm and 245 nm which are attributed to π- π* transitions of C=C (aromatic sp2 
domains). The E-CNDs and U-CNDs shows strong broad peaks at 350 nm and 337 nm, 
respectively, which are assigned to n-π transitions of C=O bond involving functional 
groups with electron lone pairs.37 The UV-Vis spectrum of curcumin shows two distinct 
peaks at ~268 nm and ~426 nm corresponding to n−π* and π–π* transitions, respectively 
(Figure 3.4A).65 The UV-Vis spectrum of Curc-E-CNDs depicts strong peak at 356 nm 
and shoulder peak at 240 nm, respectively. Curc-U-CNDs exhibits two peaks at 343 nm 
and 427 nm (Figure 3.4A). The excitation dependent behavior at different excitation 
wavelengths gives information about the strong emission peaks. Curc-E-CNDs (Figure 
3.4B) and Curc-U-CNDs (Figure 3.4C) exhibited strong emission peaks at an excitation 
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wavelength of 360 nm and 450 nm, respectively. Unlike curcumin, both the Curc-CNDs 
are readily dispersed in water and exhibited good fluorescence stability over a time 
period of 50 days (Figure B.S6). The quantum yields of the Curc-E-CNDs (48.74%) and 
Curc-U-CNDs (6.54%) is calculated with reference to quinine sulfate (Table B.S1).66  
 
 
Figure 3.4. Photoluminescence Properties of Curc-CNDs. UV-Vis absorption spectra of E-
CNDs, U-CNDs, curcumin, Curc-E-CNDs, and l-U-CNDs (A). Excitation dependent 
fluorescence spectra of Curc-E-CNDs (0.5 mg/mL) (B) and Curc-U-CNDs (0.5 mg/mL) 
(C), respectively. 
 
The curcumin loading capacity and encapsulation efficiency for Curc-E-CNDs 
were determined to be 91.5±1.5% and 3.8±0.8% and for Curc-U-CNDs to be 81.9±1.9% 
and 3.4±0.6%, respectively. These results demonstrate good loading capacity of both 
CNDs. The curcumin release pattern of both the Curc -CNDs was firstly studied in PBS 
at two different pH (7.4 and 5) over a time course of 72 hours. High curcumin release (%) 
is observed at a pH 5 in a gradual controlled manner for both the Curc-CNDs (Figure 
3.5A-B). The enhanced drug release at pH 5 may be due to weaker interactions of Curc-
CNDs in acidic environment, which will be beneficial for curcumin to elicit it’s 
therapeutic effects in the tumor microenvironment. Slow release rate of curcumin in 
solution of pH 7.4 can be attributed to the stronger electrostatic interactions between 
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CNDs and curcumin. Initial curcumin burst release of Curc-E-CNDs and Curc-U-CNDs 
was found to be 33.1% and 33.5%, respectively at 2 hours at pH 5 using curcumin 
standard curve (Figure B.S7), which might be due to the desorption and release of surface 
curcumin into the surrounding media. Thereafter, the curcumin release from both the 
Curc-CNDs followed a controlled sustained release pattern which can be attributed to the 
lipophilic nature of curcumin (Figure 3.5). A total of 59.9% and 74.3% of curcumin was 
released at 72 hours from Curc-E-CNDs and, Curc-U-CNDs, respectively. The slower 
controlled release of curcumin from Curc-E-CNDs can be exlained by the stronger 
interactions between the E-CNDs and curcumin in comparison to U-CNDs and curcumin 
due to more amine groups in E-CNDs. The drug release behavior was studied by fitting 
the curcumin release with kinetic models. The curcumin release data were plotted using 
Korsmeyer and Peppas equation with R2 values of 0.98-0.99 and n values below 0.45 for 
both the types of Curc CNDs at pH of 5 and 7.4 (Figure B.S8 & B.S9).  The n values less 
than 0.45 (n<0.45) confirms the fickian diffusion of the solute molecule (curcumin) from 
Curc-CNDs complex into the surrounding media due to chemical gradient. A similar 
release trend is observed when the Curc CNDs are suspended in EMEM cell culture 
media, with n values less than 0.45 (Figure 3.5C-D). Almost 90 % of curcumin is 




Figure 3.5. Release Profile. Curcumin release profile of Curc-E-CNDs (A) and Curc-U-
CNDs (B) under two different pH-5 & 7.4 in PBS and Curc-E-CNDs (C) and Curc-U-
CNDs (D)in EMEM media. Inserts in (C) and (D) are Korsmeyer-Peppas release model 
of Curcumin. All the data values were done in triplicates with mean ±SDs. 
 
Biocompatibility of the CNDs and Curc-CNDs were analyzed using CCK-
8viability assay for the normal cell line EA. hy926. The cells showed no significant signs 
of cellular toxicity on treatment with the CNDs and Curc-CNDs even at high 
concentration of 3.2 mg/mL (Figure 3.6A). In concert, HepG2 and A549 cells were 
treated with CNDs and Curc-CNDs at concentrations of 0.1, 0.2, 0.4, 0.8, 1.6, and 3.2 
mg/mL for 24 hours. The number of viable cells decreased in Curc CNDs treated HepG2 
and A549 cells in comparison to the CNDs treated cells (Figure 3.6B-C) from the alamar 
blue assay. At a concentration of 3.2 mg/mL, the cell viability is around 40% and 30% 
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for the HepG2 cells treated with Curc-E-CNDs and Curc-U-CNDs (Figure 3.6B), 
respectively. A549 cells displayed a cell viability of ~38% and ~18% when treated with 
Curc-E-CNDs and Curc-U-CNDs (Figure 3.6C) at a maximum concentration of 3.2 
mg/mL for 24 hours, respectively. A more rapid decrease in the number of viable cells is 
observed in both the cells treated with Curc-U-CNDs in comparison to Curc-E-CNDs 
(Figure 3.6C). The A549 cell viability assay was carried on for an extended period of 48 
and 72 hours to observe the effects of Curc-CNDs on cell viabilty. Curc-E-CNDs treated 
cells shows a cell viability of ~30% and ~25%, while Curc-U-CNDs depicts ~5% and 
~2% at a concentration of 3.2 mg/mL, at time period of 48 and 72 hours, respectively 
(Figure B.S10). Cancer cells treated with the Curc-CNDs showed cytotoxicity due to the 
higher uptake and release of curcumin compared to normal cells. This might be attributed 
to membrane structure and protein composition differences and low pH in the cells.67 The 
presence of high levels of glutathione in tumor cells enhances the sensitivity of tumor 
cells to curcumin.68 Upon treatment with Curc-CNDs, both HepG2 and A549 cells 
showed dose-dependent increase in cellular toxicity, high cellular toxicity of the Curc-U-
CNDs can be attributed to the more release of curcumin, which was observed from the 
release profile. The mechanism of cytotoxicity of curcumin in cancer cells is dependent 
on the type of cancer being treated. Specifically, in liver cancer cell lines curcumin 
suppress tumor cell survival and proliferation through inhibition of NF-κB signaling 
pathway.69 Whereas in lung cancer cells, curcumin inhibits cell proliferation and induces 




Figure 3.6. Cell Viability Assays. Cell viability assays of EA. hy926 (A), HepG2 (B) and 
A549 (C) cells treated with different concentrations of E-CNDs & Curc-E-CNDs and U-
CNDs & Curc-U-CNDs for 24 hrs. 
 
The cellular uptake studies of Curc-E-CNDs and Curc-U-CNDs were conducted 
using two cell lines HepG2 and A549 at concentrations of 0.4, 0.8, and, 1.6 mg/mL. Both 
the types of Curc-CNDs show good cellular uptake in HepG2 and A549 cells (Figure 3.7 
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& 3.8). Cells treated with Curc-E-CNDs exhibited high fluorescence intensity compared 
to Curc-U-CNDs, which is due to the high quantum yield of Curc-E-CNDs. 
 
 
Figure 3.7. Confocal Images of HepG2 Cells. Fluorescence images of live and dead 
HepG2 cells incubated with E-Curc & Curc-U-CNDs at different concentrations (0.4 (A), 
0.8 (B), and 1.6 (C) mg/mL) for 12 hours. 
 
The cellular toxicity of Curc-CNDs was evaluated using live dead assay in two 
cell lines HepG2 and A549. Curc-CNDs exhibited cytotoxicity in a dose dependent 
manner in both the cell types. As the concentration of Curc-CNDs was increased, the 
number of dead cells increased gradually. At a concentration of 1.6 mg/mL, both the 
Curc CNDs showed significant decrease in number of viable cells (Figure 3.7 & 3.8) and 
A549 cells showed change in the cell morphology (Figure 3.8C). 3.2 mg/mL 
concentration was also tested, but the cells were all detached from the cover slip after the 
treatment, due to the high toxicity of Curc CNDs. The fluorescent microscope images 
show Curc-CNDs are found to be distributed both in cytoplasm and nucleus (Figure 3.7 
& 3.8). With increase in concentration of Curc-CNDs, the cellular toxicity increased 
along with cellular uptake which is evident from live/dead assay. The results in more 
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amounts of curcumin localized in the cells, which might induce dose dependent DNA 




Figure 3.8. Confocal Images of A549 Cells. Fluorescence images of live and dead A549 
cells incubated with Curc-E- & Curc-U-CNDs at different concentrations (0.4 (A), 0.8 
(B), and 1.6 (C) mg/mL) for 12 hours. 
 
Conclusion 
In the current study, curcumin loaded CNDs were prepared in an cost-effective 
manner, to enhance the bioavailability of curcumin and explore the antiproliferative 
effects of encapsulated curcumin. The characterization studies confirmed the successful 
conjugation of curcumin with CNDs with overall small size, high loading capacity, good 
photoluminescence properties and stability. The curcumin release studies have shown 
better release of curcumin in solution with pH-5, inferring more amount of drug might be 
released in tumor microenvironment compared to normal tissues. The CNDs used for 
curcumin loading shown to be non-toxic to normal cells, thereby proving a better vehicle 
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for curcumin delivery. Curc-U-CNDs have shown enhanced cellular toxicity even at low 
concentrations which is further supported by the zeta potential measurements (longer 
circulation times) and drug release profile of curcumin, and can be attributed to the 
effective loading of curcumin onto the functional group rich CNDs. In conclusion, the 
CNDs can be valuable vehicles for curcumin delivery with enhanced bioavailability, 
small size, high encapsulation capacity, better photoluminescence, and biocompatibility, 
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ELUCIDATION OF ANTI-PROLIFERATIVE AND ROS REGULATION 
ACTIVITY OF PHOTOLUMINESCENT CURCUMIN NANOPARTICLES 
 
Overview 
Recently, various types of nanomaterials have been employed to design delivery 
vehicles for curcumin to address the problems of poor bioavailability, low aqueous 
solubility, and rapid metabolism. The present study focussed on the direct one pot 
synthesis of curcumin nanoparticles (E-Curc dots) without delivery vehicles and elucidate 
it’s therapeutic properties. E-Curc dots were synthesized using three precursor molecules, 
curcumin, ethylene diamine (EDA) and citric acid and characterized. The as-synthesized 
E-Curc dots exhibited bright blue fluorescence due to the incorporation of nitrogen from 
EDA precursor molecule. The characterization studies showed even distribution of dots 
with size less than 10 nm and reatined some of the major characteristic peaks of native 
curcumin. The synthesized E-Curc dots showed antioxidation activity at low 
concentrations (0.01-0.04 mg/mL) with low levels of ROS generation. At high 
concentrations, the dots exhibited pro-oxidant effects on both the cancer cells and normal 
cells through the generation of more ROS and dose dependent cytotoxicity is observed. 
The E-Curc dots showed better cytotoxicity towards cancer cells compared to native 
curcumin. The dots were uptaken by both the cancer and normal cells. The results clearly  
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showed the efficacy of E-Curc dots as an anti-proliferative and ROS regulator with possible 
applications in bioimaging. 
Introduction 
Reactive oxygen species (ROS) such as H2O2, NO, O2
-, HOCl, and OH- contain 
reactive oxygen molecule and are produced not only when the cells are under stress but 
also during the cellular metabolism.1-2 Cellular immune responses release free radicals, 
which in low amounts1 are beneficial to cells by inhibiting growth of viruses, pathogens 
and tumors.3 ROS also plays an important role as regulatory mediators in signaling 
pathways such as cell proliferation, activation and migration.2 The detrimental effects of 
ROS are observed only in high amounts, causing irreparable damage to cellular structures 
such as carbohydrates, proteins, nucleic acids (DNA and RNA), and lipids.4 Inbuilt 
antioxidant mechanisms, effective against blocking the damaging effects of ROS are 
altered during oxidative stress leading to various pathological conditions such as cancer, 
neurological disorders,5 asthma,6 atherosclerosis and hypertension.4 Widely used 
exogenous antioxidants such as butylated hydroxyanisole (BHA), butylated 
hydroxytoluene (BHT) are toxic and causes liver damage and carcinogenesis.7 So, the 
search for natural, safe and effective  atioxidants to counterbalance the ROS effects is 
extensive. 
Curcumin, a natural polyphenolic spice obtained from tropical southeast Asian 
plant Curcuma Longa (turmeric) has its applications dated back to centuries as a dietary 
supplement8 with its anti-inflammatory,9 analgesic, antiseptic and antioxidant 
properties.10-13 Curcumin has been reported to play an important role in radical 
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scavenging,14 metal chelation and inhibition of lipid peroxidation.12  Antioxidant genes 
such as HO-1, γ-GCS has been upregulated by curcumin during oxidative stress.10, 15 
Although, curcumin’s role as an antioxidant is well studied, few reports suggest curcumin 
can also act as pro-oxidant through the production of ROS.16-18 Phase I clinical trials in 
humans showed no side effects upon administration of curcumin (8 g/day).19 Despite all 
these pleiotropic effects of curcumin, the low aqueous solubility, poor bioavailability,20 
and rapid degradation, fast metabolism,21 and systemic elimination renders this elixir 
drug usage as a therapeutic agent.22-23 
Extensive research has been focussed on enhancement of curcumin bioavailability 
using various formulations such as micelles,24 phospholipids,25 liposomes,26 emulsions,27 
and polymers.26 However, low encapsulation efficiency, carrier instability, poor drug 
loading capacity and drug release are the challenges that need to be addressed.28-30 
Recently, nanoformulations of curcumin has gained lot of attention due to their increased 
bioavailability, solubility, circulation times, targeted specificity, decreased 
biodegradation, better photostability, and improved cellular uptake.31-38 Metallic 
nanoparticles were used as vehicles for curcumin delivery,39 but their usage is limited by 
particle instability, impurities, longer retention time and biocompatibility issues. Carbon 
nanodots (CNDs) are minute fluorescent particles in the size range of 1-10 nm with some 
unique characteristics such as aqueous solubility, chemical inertness, stable 
photoluminescence, and better biocompatibility. Small size, large surface area and 
oxygen containing functional groups (-OH and -COOH) of the CNDs acts as a better 
platform for the encapsulation and targeted delivery of curcumin.  
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The work is focussed on economical one pot synthesis of curcumin nanoparticles 
(E-Curc dots) using three precursors, ethylene diamine (EDA), citric acid and curcumin 
to enhance the bioavialability and efficacy of curcumin. E-CNDS from our previous 
study, showed high quantum yield of 64% when EDA and citric acid were used as 
precursor molecules.40 In the present study, EDA acts as a nitrogen dopant in the 
synthesis process making E-Curc dots photoluminescent and provides applications in 
bioimaging. The as-synthesized E-Curc dots were well characterized and antioxidant 
properties were investigated using DPPH. EA. hy926 (normal cell line) and A549 (lung 
cancer cell line) were used for biocompatibilty, ROS levels measurement, and 
intracellular studies. The synthesized E-Curc dots exhibited both antioxidant and pro-
oxidant activity in a concentration dependent manner.  
Methods and Materials 
Citric acid (ACROS Organics), Ethylenediamine (Fisher Scientific), Curcumin 
(Chem Cruz), α, α-diphenyl-β-picrylhydrazyl (DPPH), and dichloromethane (DCM) 
(Alfa Aesar), phosphate buffer solution (PBS) (Life Tech), quinine sulfate dihydrate, 
DCF-DA (Sigma), methanol, gold electrode, Ag/AgCl reference electrode, and platinum 
electrode (Fisher Scientific), A549 cell line, EA. hy 926 cell line, DMEM media, and F12 
K, (ATCC), pen/strep solution, fetal bovine serum and alamar blue, dimethylsulfoxide 
(DMSO) (Thermo Fisher Scientific), tryplE (Gibco). 
E-Curc dots were synthesized using ethylene diamine (EDA), curcumin and citric 
acid using one step microwave synthesizer (CEM Corp 908005 Microwave Reactor). 
Briefly, 960 mg of citric acid was dissolved in 1 ml of deionized water followed by 
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addition of 1 ml of EDA. To this solution, 2 ml of curcumin dissolved in 
dicholoromethane (10 mg/mL) was added and the mixture was pyrolyzed for 15 min at 
temperature below 150 ºC and 300 W power. The brown colored solution was dissolved 
in 5 ml of deionized water and dialyzed through MWCO 1000 membrane (Scientific 
Fisher) for 24 hrs. The solution was lyophilized for 24 hours using a freeze drier 
(Labconco Free Zone 6 Freeze Dryer). 
Atomic Force Microscopy (AFM, Agilent 5600LS AFM) in tapping mode and 
Transmission Electron Microscopy (TEM, Carl Zeiss Libra 120 Plus) were used for the 
size characterization and distribution of the synthesized dots respectively. Surface 
functional groups were investigated using fourier transform infrared (FTIR) spectra 
(Agilent FTIR). XPS (Thermo Scientific ESCALAB Xi+) and EDX (Bruker Nano XFlash 
Detector 5030) were used for the elemental composition and surface states of the as 
prepared E-Curc dots, respectively. Zeta potential of the E-Curc dots (0.01mg/mL) was 
measured using Malvern Zetasizer ZEN3600. The optical properties were measured using 
UV-Visible spectroscopy (Varian Cary 6000i) and fluorescence spectrophotometer 
(Horiba FluoroMax-4). Excitation-dependent behavior of the as prepared E-Curc dots 
(0.01 mg/mL) was determined using a fluorescence spectroscopy at different excitation 
wavelengths ranging from 300-480 nm. The quantum yield of the E-Curc dots was 
calculated with quinine sulfate as a standard using the formula:41-42 
 











where, Φ represent the quantum yield, Grad is the slope from the plot (integrated 
fluorescence intensity vs absorbance) and η, refractive index (water, 1.33). The subscript 
QS and C denoted quinine sulfate and E-Curc dots respectively.  
2,2- Diphenyl-1-icrylhydrazyl (DPPH) free radical assay was carried out to study 
the antioxidant activity of E-Curc dots. 50 µM of DPPH in methanol was added to 
different concentrations (0, 0.005, 0.01, 0.02, 0.04, 0.05 mg/mL) of E-Curc dots and 
incubated in dark environment for 1.5 hours with appropriate controls. Later the samples 
were analyzed for decrease in absorbance at 517 nm using UV-vis spectrophotometer 
with increase in the concentration. Antioxidant activity was calculated using the 
following formula. 
 
% Anti − oxiadtion activity = 1 −
Ac
A0
∗ 100 (4.2) 
 
where A0 and AC corresponds to absorbance of DPPH without and with presence of E-
Curc dots respectively. 
Cyclic Voltammetric (CV) experiments were performed using a three-electrode 
system, with gold working electrode, Ag/AgCl reference electrode and a platinum 
counter electrode. Methanol and 40mM PBS in 1:1 ratio was used as an electrolyte for all 
the experimental runs. A final concentration of 50 µM DPPH was added to each 
concentration of the E-Curc dots to be tested. Prior to the CV run, the samples were 
incubated in dark environment for 60 min. DPPD in methanolic PBS without E-Curc dots 
was used as a control. All the samples were run at seven different scan rates.  
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A549 and EA. hy926 cells were cultured in F12K medium and Dulbecco’s 
Modified Eagles Medium (DMEM) supplemented with 10% fetal bovine serum (FBS) 
and 1% pencillin/streptomycin solution respectively. All the cell lines were maintained in 
an incubator with 5% CO2 and 37 ºC in a humidified atmosphere.  
Cellular cytotoxicity studies were carried out for the synthesized E-Curc dots 
using EA. hy926 and A549 cell lines. Briefly, 10,000 cells were plated per each well in 
96 plate supplemented with the complete media and incubated for overnight. Cells were 
treated with different concentrations (0, ,0.1, 0.2, 0.4, 0.8, 1.6 mg/mL) of E-Curc dots for 
24 hours. The cells were treated with native curcumin dissolved in DMSO (0.2 mg/mL) 
for comparison with the E-Curc dots treatment group. Alamar blue assay determines the 
quantitative measurement of cell proliferation by reducing blue non-fluorescent resazurin 
to fluorescent resorufin in presence of cellular metabolic reactions.43 The cell viability 
was determined by measuring the fluorescence at an excitation wavelength of 560 nm 
and emission wavelength of 590 nm which is proportional to the number of living cells. 






∗ 100 (4.3) 
 
Intracellular ROS levels were monitored in A549 and EA. hy926 cells using 
DCFH-DA, a peroxide/hydroperoxide probe. Briefly, 10,000 cells were plated in 96 well 
plate per each well and grown for 24 hours. The cell culture medium was replaced with 
20 µM of Dichloro-dihydro-fluorescein diacetate (DCF-DA) in FBS free media and 
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incubated for 30 minutes at 37 ºC. The cells were washed with 1x PBS twice and treated 
with different concentrations of E-Curc dots for 8 hours. The cells were washed twice 
with 1x PBS and the fluorescence intensity resulting from the oxidation of DCF-DA to 
DCF was measured at an excitation of 485 nm and emission wavelength of 530 nm. As 
controls, the cells without E-Curc dots treatment and the E-Curc dots treated cells without 
DCF-DA were used. As negative control, cells were treated with ascorbic acid (AA) for 
comparison. The effect of E-Curc dots on H2O2 induced ROS production was observed 
by treating the cells with 200 µM of H2O2 after treatment with E-Curc dots and before the 
addition of DCF-DA. Normalized fluorescence intensity was calculated. 
E-Curc dots intracellular uptake was observed using confocal microscopy. 
Briefly, 1 ×105 cells (EA. hy926 and 549) were plated on cover slip in each well of 12 
well plate and incubated overnight. The medium was replaced with different 
concentrations of E-Curc dots () and incubated for 12 hours. The images were collected 
at 20X magnification using confocal microscope (Zeiss Z1 Spinning Disk Confocal 
Microscope). 
Results and Discussion 
The size of the E-Curc dots is around 6 nm from the height profile of AFM with 
an even dispersion (Figure 4.1A & 4.1B). Since the radius of curvature for the AFM 
probe is smaller, only height data is used for the size determination. The TEM analysis 





Figure 4.1. AFM and TEM of E-Curc Dots. AFM image of E-Curc dots (A) and the 
respective height profile (B). TEM image of E-Curc dots (C) with size histogram (D). 
 
The XPS survey spectrum of E-Curc dots demonstrate the presence of C1s, N1s 
and O1s peaks at 285.0, 400.5, and 532.0 eV respectively (Figure 4.2A). High resolution 
C1s spectrum of E-Curc dots depicts three surface groups corresponding to C=C, C-C/C-
H, C-OH, and O-C=O at 284.0 eV, 285.5 eV, 286.8 eV, and 288.8 eV respectively 
(Figure 4.2B). The appearance of C=C peak in the synthesized E-Curc dots indicates the 
presence of curcumin.44 Moreover, the peaks C-OH and O-C=O confirms the presence of 
alcoholic and carbonyl (keto) functional groups of curcumin (Figure C.S1).45 The high 
resolution O1s spectra shows four deconvolution peaks at 530.4 eV, 532.4 eV, and 534.3 
eV, correlate to adsorbed oxygen, O=C, and O-H respectively (Figure C.S2A). The 
79 
 
HRN1s spectrum depicts two peaks corresponding to N=C and N-C (Figure C.S2B). The 
XRD pattern of the E-Curc dots showed similar elemental compositions as of the XPS 
spectra (Figure C.S3). 
 
 








The zeta potential of the synthesized E-Curc dots is found to be -15.9±1.07 mV, 
while the E-CNDs has a potential of -25.3±1.54 mV. FTIR spectral analysis of the 
curcumin (Figure 4.3) shows its characteristic peaks at 3505 cm-1 (phenolic O-H 
stretching), 1625 cm-1 (aromatic C=C stretching), 1427 cm-1 (olefinic C-H bending), 1270 
cm-1 (aromatic C-O stretching), and 1025 cm-1 (C-O-C stretching). The characteristic 
bands of the E-CNDs at 3000-3400 cm-1 (stretching vibrations of O-H and N-H), 1538 
cm-1, 1432 cm-1, and 1375 cm-1 corresponds to the bending vibrations of N-H, C-N, and 
C-H respectively. The synthesized E-Curc dots (Figure 4.3) retained major bands of the 
curcumin and E-CNDs, clearly indicating the incorporation of curcumin. The 
disappearance of peak at 3505 cm-1 in the E-Curc dots may be due to the interaction of 
phenolic O-H of curcumin with COOH of the citric acid.  
 
 
Figure 4.4. Photoluminescent Properties of E-Curc Dots. UV-Vis absorption (blue) and 
PL emission (black) spectra of E-Curc dots (0.01 mg/mL) at an excitation of 390 nm (A). 
Wavelength dependence of E-Curc dots at different excitation wavelengths (B). 
 
E-Curc dots show strong absorption peak at 350 nm corresponding to the n-π 
transitions and shoulder peak at 250 nm attributing to the π- π* transitions of C=C 
(aromatic sp2 domains) (Figure 4.4A). The shoulder peak at 460 nm attributes to the 
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curcumin incorporated into the CNDs. The emission peak was observed at 450 nm with 
an excitation wavelength of 390 nm (Figure 4.4A). The wavelength dependence of E-
Curc dots was performed at different excitation wavelengths ranging from 300-480 nm 
(Figure 4.4B). The high intensity emission peak occurs at an excitation wavelength of 
390 nm. The quantum yield of the as-synthesized E-Curc dots is 45.5±2.1% with 
reference to quinine sulfate (54%). 
 
 
Figure 4.5. DPPH Antioxidation Assay. UV-Vis spectra of DPPH in methanolic solution 
at various concentrations of E-Curc dots (0, 0.005, 0.01, 0.02, 0.04, 0.05 mg/mL) (A). 
Antioxidant activity of E-Curc dots with their respective concentrations (B). 
 
E-Curc dots antioxidation activity was assessed with DPPH assay using UV-Vis 
spectrophotometer. DPPH is a stable free radical with an unpaired valence electron at 
nitrogen bridge and has a bright purple color when dissolved in methanol. The basic 
principle is scavenging of antioxidant compounds, through the transfer of hydrogen atom 
of the antioxidant molecule to the hydrazine of the DPPH, thereby changing it’s color 
from deep purple to yellow.46 With increase in the concentrations of E-Curc dots, the 
absorption peak decreases at 515 nm (Figure 4.5A). The antioxidant activity % of E-Curc 
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dots is found to be 24.0, 49.6, 70.1, 79.0, 87.2% at concentrations of 0.005, 0.01, 0.02, 
0.04, 0.05 mg/mL respectively (Figure 4.5B). At a concentration of 0.05 mg/mL the 
absorption peak flattened with 87.2% antioxidant activity and the color of the DPPH 
solution turned yellow. The rapid decrease in the absorbance peak might be attributed to 
the anti-oxidant nature of curcumin incorporated into the dots.  
 
 
Figure 4.6. Cyclic Voltammograms of E-Curc Dots. Cyclic voltammograms of E-Curc 
dots in methanolic DPPH at different concentrations of 0 (A), 0.01 (B), 0.02 (C), 0.04 
(D), 0.06 mg/mL (E) at scan rates of 0, 20, 50, 100, 200, 400 and 500 mV/s. Cyclic 
voltammograms of E-Curc dots in methanolic DPPH at different concentrations (0, 0.01, 
0.02, 0.04, 0.06 mg/mL) at a scan rate of 400 mV/s (F).  
 
The antioxidant activity of E-Curc dots is further supported with cyclic 
voltammetric analysis. DPPH can either act as an oxidizing or a reducing agent and most 
of the antioxidant studies showed DPPH exclusively acts as an oxidising agent.47  
 
DPPH∗ ↔ DPPH − H + e− (4.4) 
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DPPH∗ + e− ↔ DPPH− (4.5) 
 
In the absence of E-curc dots, the redox peaks in methanolic DPPH are intact 
(Figure 4.6A), but with increase in the concentration of E-Curc dots, the redox peaks 
started to decrease (Figure 4.6B-E). The clear decrease in tendency of redox peaks is 
observed with increasing concentration sof E-Curc dots at a scan rate of 400 mV/s 
(Figure 4.6F). This is due to the proton transfer from the E-Curc dots to DPPH*, 
converting free radical DPPH* to neutral stable DPPH-H. With increase in E-Curc dots, 
the available DPPH* is decreased at the electrode surface, thereby reducing the redox 
peaks. The underlying mechanism might be the hydrogen atom transfer (HAT) from the 
O-methoxy phenolic group of nanocurcumin molecule to the DPPH* free radical. 
 
E − Curc dots + DPPH∗ → DPPH − H + E − Curc dots∗ (4.6) 
 
 
Figure 4.7. Biocompatibility of E-Curc Dots. Biocompatibility of E-Curc dots tested at 




The cell viability of E-Curc dots was assessed using alamar blue assay for two 
cell lines EA. hy926 and A549. There is an increase in cell viability upon treatment with 
E-Curc dots in a concentration range 0.01-0.08 mg/mL in both the cell lines. Thereafter, 
with increase in the concentration of E-Curc dots, the cell viability decreased 
significantly in both the cell lines. A549 cells showed higher levels of cell toxicity 
compared to the EA. hy926 cells (Figure 4.7). Statistically, the cell viability is around 
72% for A549 cells and 48% for EA. hy926 cells, after incubated for 24 hours at higher 
concentration of 1.6 mg/mL. The control native curcumin in DMSO (0.2 mg/mL) showed 
93% and 83% cell viability for EA. hy926 and A549 cells respectively. The nano-
curcumin (E-Curc dots) showed better cytotoxicity towards the cancer cells at low 
concentrations (0.2 mg/mL) compared to native curcumin, suggesting the efficacy of the 
synthesized E-Curc dots. The increased cellular toxicity of the 549 cells compared to EA. 
hy926 upon treatment with E-Curc dots can be due to increased cellular uptake in cancer 
cells and moreover, cancer cells are more sensitive to oxidative stress.48 The different 
trends observed in the cell viability with E-Curc dots treatment might be attributed to the 





Figure 4.8. ROS Levels Measurement. ROS levels measurement in EA. hy926 (A) and 
A549 cells (B) on addition of E-Curc dots and ascorbic acid (AA) at different 
concentrations using DCF-DA assay. Effects of E-Curc dots at different concentrations 
on H2O2 (200 µM) treated EA. hy926 (C) and A549 cells (D). 
 
Intracellular ROS levels of EA. hy926 and A549 cells were measured using 
DCFH-DA assay upon treatment with E-Curc dots. DCFH-DA is a cell permeable non-
fluorescent probe for intarcellular oxidative stress measurement. Intracellular esterases 
cleave ester bonds of DCFH-DA into non-fluorescent impermeable DCFH2, which on 
subsequent oxidation produces highly fluorescent DCF. Accumulation of DCF in cells is 
proportional to concentration of hydrogen peroxide (H2O2) can be measured with 
increase in fluorescence 530 nm when excited at 485 nm.49 Upon treatment with E-Curc 
dots, the ROS levels are almost similar to that of control (Cells with no E-Curc dots 
treatment) in EA. hy926 cells with in a concentrtaion range of 0.01-0.04 mg/mL. Increase 
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in ROS levels were observed after 0.08 mg/mL in a concentration dependent manner. 
But, the treatment with AA (0.01, 0.02, 0.04, 0.08, 0.16, 0.32, and 0.64 mg/mL), steadily 
decreased the ROS levels in EA. hy926 cells (Figure 4.8A). Similar trend is observed 
with A549 cells, except for the ROS levels increased after treatment with E-Curc dots at a 
concenration of 0.04 mg/mL (Figure 4.8B). The protective effects of E-Curc dots 
pretreatment on cells were identified by treating the cells with 200 µM H2O2, a ROS 
inducer. Pretreatment with E-Curc dots remarkably inhibited cell cytotoxcity caused by 
H2O2 up to a concentration of 0.08 mg/mL, in both the cell lines (Figure 4.8C & 4.8D). 
With increase in E-Curc dots concentration beyond 0.08 mg/mL, the ROS levels 
increased, leading to cellular toxicity. AA showed dose dependent decrease in ROS levels 
with increase in concentration in both the cell lines (Figure 4.8C & 4.8D). 
In the present study, E-Curc dots are synthesized from curcumin precursors and 
the reduction in particle size of active ingredients to nano size might have increased the 
solubility and efficacy.50 Previous studies showed at low concentrations curcumin acts an 
antioxidant through ROS scavenging by preventing depletion of glutathione (GSH), a 
natural cellular antioxidant and at high concentrations acts an pro-oxidant with increase 
in ROS production.51 The antioxidant or pro-oxidant activity depends on structure 
modification, curcumin concentration, presence of metal ions at free radical generation.52 
The results from ROS measurement are in accordance with the cell viability data, which 
suggest the increased cytotoxicity upon treatment with higher concentrations of E-Curc 
dots might be due to the excess ROS production, making it a promising anti-cancer agent 
leading to cell death. And the high viability at low concentrations of E-Curc dots might 
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be attributed to the ROS scavenging activity. The decrease in ROS generation can be 
attributed to the abstraction of H-atom from the O-methoxy phenolic rings of curc dots to 
free radicals.53 The high ROS generation at higher concentrations of E-Curc dots ascribes 
to the presence of α,β- unsaturated ketone groups, which might alkylate active sites of 
thioredoxin reductase enzyme, rendering the enzyme from reducing thioredoxin, which 
plays an important role in regulation of ROS.17 As a result, more ROS generates within 
the system leading to cell cytotoxicity. 
 
 
Figure 4.9. Confocal Images. Live/dead assay of A549 cells treated with different 
concentrations of E-Curc dots. 
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Live/dead assay was used to determine the cellular toxicity towards E-Curc dots. 
The A549 cells were treated with different concentrations of E-Curc dots (0.2, 0.4, 0.8, 
and 1.6 mg/mL) for 24 hours. E-Curc dots were found to be sub-cellularly localized 
inside the A549 (Figure 4.9) with bright blue fluorescence. As the concentration of the E-
Curc dots increased, the fluorescence intensity increased (Figure 4.9). EA. hy926 cells 
also showed good sub-cellular localization of E-Curc dots (Figure C.S4). The cellular 
toxicity of A549 cells increased in a dose dependent manner upon treatment with E-Curc 
dots compared to controls (Figure C.S5), which can be ascribed to the more uptake of E-
Curc dots. At 1.6 mg/mL concentration, more than 50% of cells were dead, indicating the 
production of high levels of ROS (Figure 4.9). Positive control includes the cells with no 
treatment and negative control has cells teated with 200 µM H2O2.  
Conclusion 
Although curcumin offers exclusive therapeutic applications as anti-cancer, 
antioxidant, pro-oxidant, anti-microbial, and anti-inflammatory agent, it’s usage is 
limited by poor bioavailability and aqueous solubility, and rapid metabolism. In oder to 
overcome the issues, various drug delivery vehicles for carrying curcumin are developed 
using nanoparticles. In the present study, curcumin nanoparticles were synthesized in a 
cost-effective way using curcumin and ethylene diamine (EDA) as precursor molecules. 
EDA acts as a nitrogen dopant in the synthesis process making E-Curc dots 
photoluminescent and provides applications in bioimaging. The synthesized E-Curc dots 
retained some of the functional groups of native curcumin and demonstrated stable 
photoluminescence, with size less than 10 nm. The curcumin dots showed excellent 
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antioxidation capacity at very low concentrations (0.05 mg/mL) as measured by DPPPH 
assay. In terms of therapeutic efficacy, E-Curc dots proved to act as both antioxidant and 
pro-oxidant at low and high concentrations respectively, which is in accordance with the 
cell viability data. Chemo-protective nature of E-Curc dots was observed when the cells 
were treated with H2O2. Moreover, the E-Curc dots were successfully uptaken by cancer 
cells with bright blue fluorescence. Overall, the synthesized E-Curc dots retained the 
characteristics of native curcumin a ROS regulator with stable photoluminescence and 
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 The thesis work concentrates on the various applications of CNDs in the fields of 
biosensing, drug delivery and radical regulation utilizing their unique properties. 
With distinct advantages of high sensitivity, selectivity, biocompatibility, simple 
and cost-effective synthesis, CNDs finds its application in metal ion detection. Chapter II 
signifies the role of CNDs in iron biosensing and the underlying detection mechanism 
was studied using cyclic voltammetry, an electrochemical technique for the first time. 
The photoluminescence phenomenon of CNDs is utilized for the detection of iron. Up on 
addition of Fe (III) ions, the fluorescence intensity of CNDs decreased in a dose 
dependent manner with a short response of 1 minute. The quenching efficiency displayed 
a linear relationship with Fe (III) ion concentration in a broad range of 1-2000 μM. The 
synthesized nanoprobes showed excellent selectivity with no interference with the other 
metal ions. Iron content in real samples such as tap water and human serum was detected 
using the nanoprobes. The Fe (III) content in living cells was also monitored, which can 
serve as an effective nanosensor for intracellular Fe (III) sensing. The quenching 
mechanism of CNDs up on addition of Fe (III) was elucidated using cyclic voltammetry. 
Charge transfer (electron transfer) occurs at the working electrode between the CNDs and 
Fe (III) ions upon formation of CND-(Fe (III))n complex and results in the formation of
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 E-CND-(Fe (II))n complex. The diffusion of E-CND-(Fe (II))n complex to the working 
electrode slows down compared to the free available Fe (III) in the solution thereby 
decreasing the redox peaks. This proposed mechanism provides a better understanding of 
the detection of different biologically significant metal ions. 
In chapter III, CNDs were used as a drug delivery vehicle to load curcumin to 
deliver to the target site with minimal side effects. Curcumin, a natural antioxidant with 
anti-cancer, and anti-inflammatory properties confounds its therapeutic efficiency due to 
poor bioavailability, rapid metabolism and poor pharmacokinetics. Various delivery 
vehicles have been formulated for enhancement of curcumin, but the stability and low 
drug loading capacity is often questionable. For the first time, photoluminescent CNDs 
were employed for the loading of curcumin and to enhance its bioavailability. CNDs 
showed an encapsulation efficiency of about 92% with enhanced release in acidic media, 
which confers the high release of curcumin at tumor site to elicit its anti-cancer effects. 
The slow controlled release pattern of curcumin observed allows curcumin to reach its 
target site without getting wasted in the biological system. Curc CNDs were well 
internalized inside the cancer cells and showed dose dependent cytotoxicity in cancer 
cells without affecting normal cells. This new approach-based CNDs delivery systems 
could improve the bioavailability, and stability of several other hydrophobic drugs to 
elicit their therapeutic effects. 
In chapter IV, curcumin nanoparticles (Curc dots) were synthesized from native 
curcumin using two precursor molecules EDA and citric acid. EDA acted as a nitrogen 
dopant in the synthesis making these dots photoluminescent and finds applications in 
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bioimaging. The antioxidant properties were evaluated using DPPH assay and verified by 
cyclic voltammetry. Curc dots elicited better anti-proliferative effects on cancer cells 
compared to native curcumin which might be due to the reduction in particle size of 
active ingredients to nano size thereby increasing the solubility and efficacy. The 
concentration dependent antioxidant and pro-oxidant effects of synthesized curc dots 
were in accordance with the cell viability assays, which suggest the increased 
cytotoxicity upon treatment with higher concentrations of Curc dots might be due to the 
excess ROS production, making it a promising anti-cancer agent leading to cell death. 
The mechanism behind the excess ROS generation might be due to the alkylation of 
active site of thioredoxin reductase enzyme by E-Curc dots. The depletion of the enzyme 
could not reduce thioredoxin, a compound that regulates ROS levels. And as a result, pro-
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Figure A.S1. The Plot of Integrated Fluorescence Intensity vs Absorbance as a 





Figure A.S2. N1s and O1s XPS Peaks of CNDs. N1s and O1s XPS peaks of E-CNDs (A, 
















Figure A.S3. EDX Analysis. EDX analysis of E-CNDs (A) and U-CNDs (B) on silicon 










Figure A.S4. FTIR Spectra of CNDs. FTIR spectra of E-CNDs (A) & U-CNDs (B).  
 
    
Figure A.S5. Excitation Dependent PL Spectra. Emission spectra of E-CNDs (A) & U-










Figure A.S6. Time Course Response. Time course response of fluorescence upon 




Figure A.S7 Absorption Spectra of CNDs. Absorption spectra of E-CNDs (0.1mg mL-1) 







Figure A.S8. Linear Korsmeyer-Peppas Plots. Linear plot of E-CNDs (0.01 mg mL-1) (A) 
and U-CNDs (0.1 mg mL-1) (B) between (F0-F)/F and Fe (III) at low concentration range 
of 0.01 – 0.2 µM for E-CNDs, and 0.01  – 0.5 µM for U-CNDs. 
 
         
  
Figure A.S9. Quenching% in Presence of Metal Ions. Quenching% (averaged) of 
fluorescence of 0.05 mg mL-1 E-CNDs (A) and 0.1 mg mL-1 U-CNDs (B) in presence of 
different metal ions (50µM). Interference of E-CNDs (C) and U-CNDs (D) fluorescence 





      
Figure A.S10. Detection of Fe (III) in Real Samples. Detection of Fe (III) in tap water and 
human serum using E-CNDs (A) and U-CNDs (B) probes. 
 
 
Figure A.S11. ICP Calibration Plot. Fe (III) calibration plot from ICP spectroscopic 






             
           
Figure A.S12. Fluorescence Spectra of CNDs. Fluorescence spectra of E-CNDs and U-







Figure A.S13. Cyclic Voltammograms of Fe (II) Treated with E-CNDs. Cyclic 
voltammograms of Fe (II) treated with 0.00 (A), 0.02 mg mL-1 (B) concentrations of E-









Figure A.S14. Cyclic Voltammograms of Fe (II) Treated with U-CNDs. Cyclic 
voltammograms of Fe (II) treated with 0.00 (A), 0.2 mg mL-1 (B) concentrations of U-








Figure A.S15. Cyclic Voltammograms of Cu (II) Treated with E-CNDs. Cyclic 
voltammograms of Cu (II) (10 mM) treated with 0.00 (A), 0.1 mg mL-1 (B) 
concentrations of E-CNDs at different scan rates of 10, 20, 50, 100, 200, 500, and 1000 











Figure A.S16. Cyclic Voltammograms of Cu (II) Treated with U-CNDs. Cyclic 
voltammograms of Cu (II) (10mM) treated with 0.00 (A), 0.1 mg mL-1 (B) concentrations 









Table A.S1. Comparison of Various Nanoparticles as Sensing Probe for the Detection of 
Fe (III) Ions 
Sensing Probe Dynamic 
Detection 
Range (µM) 




B, N, S Doped Carbon 
Dots 
0.3-546 0.09 5.44 1 
N-doped Carbon Dots 1-250 0.52  16.4 2 
N-doped carbon dots 0.01-500  0.0025  31 3 
N & P co-doped dots 0.005-0.1  0.0018  30 4 
Sulfur doped graphene 
dots 
0-0.7  0.0042  10.6 5 
N & S doped carbon 
dots 
40-700  0.03  14.3 6 
N & Zn doped carbon 
dots 
0.05-125  0.027 63.28 7 
Green emitting CDs 25-300 19 46.4 8 
N-CDots 0-50 0.007 34.8 9 
S-doped C-dots 1-500 0.1 67 10 
Fluorescent carbon dots 0-185 6.16 80 11 
N doped carbon dots 0-6  0.034 2.15 12 
N doped carbon dots 0.05-30  0.013 41 13 
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DESIGN OF CURCUMIN LOADED CARBON NANODOTS 
DELIVERY SYSTEM: ENHANCED BIOAVAILABILITY, RELEASE 
KINETICS AND ANTICANCER ACTIVITY 
 
   
Figure B.S1. FTIR Comparison Spectra. FTIR spectra of Curc-E-CNDs (A) and Curc-U-
CNDs (B) with their respective precursor CNDs. 
 
  
Figure B.S2. Raman Spectra of Curc-CNDs. Raman spectra of Curc-E-CNDs (A) and 






     
Figure B.S3. XPS Spectra. XPS survey spectrum of curcumin (A) and high resolution 
C1s (B) and O1s (C) peaks of curcumin respectively. 
 
          










               
               
Figure B.S5. XPS Spectra of Curc-CNDs. XPS spectrum of high resolution O1s (A, C) 
and N1s (B, D) peaks of Curc-E-CNDs and Curc-U-CNDs respectively. 
 
      
Figure B.S6. Fluorescence Stability. Fluorescence stability of Curc-E-CNDs (A) and 












Figure B.S7. Curcumin Standard Curve in Methanol Solvent. 
 
    
Figure B.S8. Release Model of Curc-E-CNDs. Korsmeyer-Peppas release model of 
Curcumin from Curc-E-CNDs at pH-7.4 (A) & pH-5 (B) respectively. All the data values 





    
Figure B.S9 Release Model of Curc-U-CNDs Korsmeyer-Peppas release model of 
Curcumin from Curc U-CNDs at pH-7.4 (A) & pH-5 (B) respectively. All the data values 
were done in triplicates with mean ±SDs. 
 
  
Figure B.S10. Cell Viability Assays. Cell viability of A549 cells treated with different 
concentrations of E-CNDs & Curc-E-CNDs and U-CNDs & Curc-U-CNDs for 48 (A) & 















Table B.S1. Quantum Yields of CNDs Before and After Functionalization with Curcumin 
with Reference to Quinine Sulfate. 
Sample Quantum Yield 









ELUCIDATION OF ANTI-PROLIFERATIVE AND ROS 




Figure C.S1. XPS Spectra. XPS survey spectra (A) and high resolution C1s (B) and O1s 
(C) peaks of curcumin respectively. 
 
 
Figure C.S2. XPS Spectra of O1s (A), N1s (B) of E-Curc Dots.





Figure C.S3. XRD Pattern of E-Curc Dots. 
 
 
Figure C.S4. Subcellular Localization of E-Curc Dots. Subcellular localization of E-Curc 





Figure C.S5. Controls of Live/Dead Assay for A549 Cells. 
